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1Summary
Transforming growth factor β (TGF-β) signaling regulates numerous cellular and
physiological processes. Dysfunction of components of this signaling pathway leads to
a wide range of diseases ranging from malignant hematopoiesis, cardiovascular disease,
immunity abnormalities, connective tissue disease, reproductive disorders, metabolic
disorders, skeleton and muscular disorders, to developmental defects.
We focused on the role of Smad4 and TBRII genes in the hematopoiesis and studied a
conditional Smad4 knockout mouse. Mice with homozygous Smad4 deletion (Smad4Δ/Δ)
developed severe anemia 6-8 weeks after induction (mean hemoglobin 70g/L). The
anemia was not transplantable, as wild type mice reconstituted with Smad4Δ/Δ bone
marrow cells had normal peripheral blood counts. In contrast, lethally irradiated
Smad4Δ/Δ mice transplanted with wild type bone marrow cells developed anemia similar
to non-transplanted Smad4Δ/Δ mice. Liver iron stores were decreased and blood was
present in stool, indicating that the anemia was due to blood loss. Multiple polyps in
stomach and colon represent a likely source of the bleeding. We conclude that Smad4 is
not required for adult erythropoiesis and that anemia is solely the consequence of blood
loss. Regulation of hepcidin related genes (Atoh8, Id1 and Bmp6) responded to acute
bleeding in the absence of Smad4, TBRII and/or histone deacetylase 1 (HDAC1) genes.
Smad4Δ/Δ mice did not develop an inflammatory disease typical for mice deficient in
T G F - b  receptors I and II (TBRI and TBRII), suggesting that suppression of
inflammation by TGF-β is Smad4 independent. The same results were obtained when
Smad4 alleles were deleted selectively in hematopoietic cells using the VavCre
transgenic mice. Mice with a double knockout (Smad4Δ/Δ and TBRIIΔ/Δ) did not display
the TBRIIΔ/Δ -driven lethal inflammation suggesting that Smad4 signaling is required to
mediate the inflammatory phenotype. Smad4/TBRII  was dispensable for the
megakaryopoiesis and erythropoiesis. Finally, we confirmed that the Smad4-signaling
pathway is required to suppress tumorigenesis in the gastrointestinal tract and loss of
Smad4-signaling in hematopoietic cells is sufficient to cause polyp formation in the gut.
2General introduction
1. TGF-β superfamily signaling
As an important and pervasive signaling pathway, transforming growth factor β (TGF-
β) superfamily signaling pathways regulate a wide range of biological processes at
cellular and systematical levels. It dictates not only the single cell’s expansion,
determination, movement and apoptosis, but also contextual interactions among
different cells, tissues and organs, which guide development, immune regulation,
tumorigenesis, and wound recovery. Malfunction in these pathways often leads to many
kinds of diseases in vertebrates.  Detailed studies of these pathways at different levels
shed light on the relevant biomarker screens and therapeutic application.
The TGF−β superfamily ligands consists of more than 30 polypeptide growth factors
including TGF−βs(1-3), activins (A, B), inhibins (A, B), bone morphogenetic proteins
(BMPs 1-9), growth differentiation factors including myostatin, nodal, leftys (1,2), and
Mullerian inhibiting substance (MIS). 1,2,3 These members show a similar cysteine
knot structure, and are universally expressed. DNA mutations or protein expression
abnormality can cause many malfunctions resulting in developmental, metabolic and
physiological disorders. 4 5
1.1 Basic signaling pathway
Signaling by TGF−β superfamily is mediated through the binding of the ligand to high
affinity heterodimeric receptors complexes that consist of seven type I (activin like
kinase (ALK) 1-7) and five type II (serine/threonine kinase) subunits. Specific and non-
specific ligands bind to different combinations of receptor complexes, forming a
complex signaling stimuli. The binding of ligands to heteromeric receptors activates
type II receptor kinase to phosphorylate the type I within a glycine and serine-rich
domain thereby initiating its kinase function to phosphorylate the downstream
messengers in Smad-dependent/independent ways.
The Smad-dependent pathway is facilitated by the membrane-bound scaffold protein
Smad anchor for receptor activation (SARA) and results in phosphorylation two
receptor-regulated Smad proteins (R-Smad), forming a complex with the common
3Smad (Smad4), which translocates into the nucleus to regulate the gene expression both
positively and negatively in association with different transcription factors, such as
members of the forkhead, homebox, zinc-finger, bHLH, and AP1 families. Under these
circumstances, the Smad4 and cytoplasmic preferred R-Smad will accumulate in even
distribution in the nucleus. The newly identified R-Smad phophatases in the nucleus are
able to release these Smads from nucleus, and end the signaling. Nevertheless, a third
class of Smad proteins, the inhibitory Smads (I-Smads), including Smad6 and Smad7,
inactivate the receptor complex by degradation via the ubiquitin ligases Smurf1/2 and
dephosphrylation via the protein phosphatase I, and interrupt the formation of R-
Smad/Smad4 complex.
TGF−β superfamily co-receptors, besides facilitating ligand binding to the signaling
receptors, are able to form morphogen gradients during embryonic development,
antagonize ligand function, direct receptor localization and internalization, mediate
cellular adhesion and orchestrate signaling.6 For example, the soluble and surface
TBRIII impacts on migration and localization of the ligand-receptor complex through
interacting with ligands like inhibin,7,8 BMP,9 and TGF−β ligands.10,11,12
1.2 Noncanonical signaling pathway
TGF−β signals in Smads-independent ways through cross talk with other signaling
pathways, such as the mitogen activated protein Kinase (MAPK) pathways, including
extracellular-signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK), the
phosphoinositide 3-kinase (PI(3)K)/Akt pathway, and the nuclear factor-kappa B (NF-
κB) pathway (Figure 1).13,14 Type II receptors play an important role in these cross-
talks, instead of type I receptors.
Furthermore, even in R-Smads-dependent pathways, some factors like TIF1γ15 and I-
kappa-B kinase a (IKKa),  as well as a component of the microRNA processing
complex DROSHA, p68, are reported to directly bind the R-Smads complex without
Smad4 to regulate the downstream genes.16
1.3 Smads-dependent signaling pathways
Smads contain a Mad homology (MH)1 and MH2 domain, which are connected by a
linker region. MH1 has a nuclear localization signal (NLS), and inhibits the MH2, 17
4the functional domain of Smads. Smads complexes can bind common DNA elements in
the promoter region, like GTCT via TGF−β activation,18 and GCCNC or GRCGNC via
BMPs activation.19
Figure 1. TGF−β superfamily signaling pathways. (cited from Blobe et al., BBA, 1782(2008)197-228)
Smads form a complex with many partners in nucleus upon activation (Table 1)
Under TGF−β signaling, Smad2&3 combined with Smad4 interact with many
transcription factors, such as FoxH1, Mix, FoxO, C/EBPβ, or repressor FoxG1, ATF3.
The activating protein-1 (Ap-1), NF-κB, runt-related transcription factor-2 (Runx2) and
signal protein-1(Sp1) were also reportedly involved in this process(Figure 2). 20,21,22
5
6Figure 2. TGF−β and BMP activated the gene regulation. (cited from Hill et al., IJBCB,40(2008)383-408)
Upon activation of BMPs signaling, Smad1-Smad4 complexes recruit co-factor such as
Drosophila Schnurri(Shn)-Mad-Medea(Med) complex or polyomavirus enhancer-
binding protein2 (PEBP2), to activate or repress genes in a cellular context-dependent
way (Figure 2).23
71.4 Post-translational modifications of the Smads
Smads are subject to many protein modifications, such as ubiquitilation, sumoylation,
acetylation and phosphorylation. These modifications are very important parts of
TGF−β signaling.
Figure 3. Post-translational modification of Smads. (cited from Hill et al., IJBCB,40(2008)383-408)
Ubiquitilation
Ubiquitilation is a covalent binding of a 76 amino acid polypeptide called ubiquitin, to
mainly lysine residues mainly of target proteins. Ubiquitilation is involved three steps,
under the control of enzyme1-3 (E1-3) respectively. E1 is for adenylation of the C-
terminus of ubiquitin, E2 for transferring and E3 for final ligation. Because of
ubiquitin’s own lysine, poly-ubiquitin chains can form and be recognized by
proteasome for target protein degradation. Besides protein degradation, ubiquitilation
can regulate the substrate trafficking, protein interaction and activity.24
Smads are often regulated by ubiquitilation. The Smad ubiquitination regulatory factors
(Smurf) E3 ligase, were reported to interact with Smad1and Smad5. Smurf1 impairs
nuclear translocation of Smad1by interfering with its binding to Nup214.25 Smurf2 can
ubiquitinate active Smad1 and Smad2 and results in their degradation.26
8Phosphorylation sites within the C-terminus and the linker region are important for R-
Smad-Smurf interaction. The PPXY motif in the linker region is recognized by Smurfs.
27
Smad3 can be ubiquitinated and degraded through mediation of the regulator of cullins-
1(ROC1), which is a component of Skp/cullin/F-box E3 ligase complex.28
However, the positive regulation by E3 ligases, like Cbl-b and Itch were observed in
TGF−β signaling. Repressor of TGF−β signaling, Sloan-kettering retrovirus proto-
oncogene product(Ski) and ski-related novel gene (SnoN), degrade through involvement
of Smurf2, anaphase promoting complex(APC) and Arkadia.29
I-Smads, Smad6 and Smad7 containing an E3 ligase recognize the motif PPXY,
undergo ubiquitin mediated degradation themselves, or mediate ubiquitin-dependent
degradation of TGF−β receptor complex and reduce TGF−β signaling.27
Like R-Smads, Smad4 can also interact with E3 ligases directly, or indirectly mediated
by R-Smad4, but without direct ubiquitination. SCF complex is quite involved in the
turn over of Smad4. Another E3 ligase, Ectodermin(Ecto/TIF1γ)15 competes with
Smad4 for binding the Smad2&3 complex to increase the erythroid differentiation. The
worthwhile fact is that wild type Smad4 is not poly-ubiquitinated, but mono/oligo-
ubiquitinated, while mutants of Smad4 undergo poly-ubiquitination resulting in
degradation.
Although E3 ligases mainly impact negatively on TGF−β signaling, positive
enhancement is also observed in Smads-independent pathway. Furthermore, the
deubiquitinating enzyme ubiquitin C-terminal hydrolase37 (UCH37) can counter-
balance with ubiquitination on Smads.30
Sumoylation
Small ubiquitin-like modifier (SUMO), a ubiquitin-related polypeptide, is another
attractive modification on target protein for signaling. SUMO competes with other
modification like acetylation and ubiquitination on lysine residues. Sumoylation of
target protein like Smad4, has increases binding affinity for histone deacetylase gene
(HDACs).31 SUMO1 or SUMO E2-conjugating enzyme Ubc9 might be involved in this
9process. Unlike the degradation function of ubiquitin, SUMO can interact with Smad4
and change its activity to interact with other transcriptional factors like repressor
Daxx,32 resulting in alter gene regulation.  Another example is Protein inhibitors of
activated STAT(PIAS) proteins, containing SUMO E3 ligase activity, which are able to
interact with Smad1-4 and enhance Smad3/4 transcription by recruiting the co-activator
proteins p300 and/or CREB-binding protein(CBP).  The fact that Smad4 is regulated via
sumoyulation implies that other substrates of sumoylation might exist in the
components of TGF−β signaling.33
Acetylation
Acetylation is widely reported lysine-specific modification on protein including the
histiones and transcriptional factors. Smad7 can be acetylated and de-acetylated by
p300 and HDAC respectively. Furthermore, Smad2 and Smad3 are also acetylated by
p300 and CBP. These acetylation can re-modify gene expression, Smads complex
stability and trafficking.
Phosphorylation
Besides the phosphorylation by type I&II receptors upon TGF−β signaling, MAPKs,
CDK and Calmodulin-depentant kinase II (CaMKII) can phosphorylate Smads.
Conversely, this phosphates group can be removed by many phosphatases like pyruvate
dehydrogenase phosphatase (PDP), RNA polymerase II small X-terminal phosphatases
SCP1-3, and PPM2A. The balance of phosphorylation and de-phosphorylation modifies
the activities of Smads, and subsequently modulates TGF−β signaling.34
Chromatin protein
Naked DNA cannot be bound by Smads complexes. It always needs the help of histone
and other chromatin protein. HAT, HDAC, and chromatin remodeling complexes like
switching of mating type/sucrose non-fermenting (SWI/SNF), imitation switch (ISWI),
nucleosomes remodeling and deacetylase (NuRD) and Ino80 are involved in Smads
mediated the regulation.35 Puzzlingly, important chromatin-modifying enzymes, such as
methylation and de-methylation enzymes, are not found to interact with Smads.
10
1.5 Regulation of TGF−β signaling
As an important and complex signaling pathway, TGF−β superfamily signaling is
regulated at all levels, including at the level of ligands, receptors and co-receptors,
Smads, as well as autocrine positive and negative feedback loop.
At the ligand level, TGF−β is not functional without cutting off a signal peptide named
the latency associated peptide domain (LAP).36Many extracellular proteases are
involved in this cleavage, such as thrombospondin-1,37plasmin, cathepsin D,38 matrix-
metalloproteinases 2 and 9,39 and furin convertase.40 It’s also reported, upon the LAP’s
binding to integrins, alphavbeta6 integrin can activate TGF−β1,41 and alphavbeta8
mediated epithelial homeostasis through MT1-MMP dependent activation of TGF−β1.42
In contrast to TGF−β, BMPs, secreted in an active form, are regulated by many
antagonists, who interact with BMPs directly and inhibit the binding their binding with
type I and type II receptors. According to the structure, these antagonists are classified
as CAN, twisted gastrulation, and chordin/noggin families.43 Because of different
affinities for BMPs and expression patterns, localization, these antagonists are able to
precisely regulated BMPs signaling in a specific time and spatial manner.44
At the levels of the receptors, FK506-binding protein 12 (FKBP12) can end signal
transmission by blocking the phosphorylation site of type I superfamily receptors from
their respective type II receptors.45,46 By clathrin-mediated endocytosis of the receptors,
SARA might enhance TGF−β signaling. However, lipid raft or caveolin-mediated
endocytosis results in receptor ubiquitination and degradation. 47Furthermore, receptor
trafficking was also mediated by TGF−β superfamily co-receptors, such as TBRIII and
endoglin through their interactions with the scaffolding proteins, GAIP-interacting
protein C-terminus (GIPC) and b-arrestin2.48
An interesting study reports that MicroRNA miR24 is targeting activin type I receptor
ALK4 expression, but regulation of miR24 is still unclear.49
At the Smad level, ErbB2/Her2-interacting protein (Erbin) antagonizes phosphorylated
R-Smads to make active complex with Smad4 .29 In addition, PPM1A de-
11
phosphorylates nuclear phosphorylated R-Smads to recycle them back to the cytoplasm.
50 A new interesting discovery is that p53 interacts with the N-terminal MH1 domain of
Smad2, and phosphorylation status of p53 is required to turn on Mix2 expression upon
TGF−β activation. This is another example showing the complexity of cross-talking
between TGF−β signaling and others signaling networks.51
Besides the above mentioned the role of PPM1A in signaling ending, I-Smads including
Smad6 and Smad7, whose increased expression upon activation of the signaling, is a
negative feedback loop by competing with R-Smads for binding to their respective type
I receptors,52 and degradation of Smads and receptors from recruited ubiquitinase of
Smurf1and Smurf2.53 In addition, TGF−β signaling induced secreted proteins, can also
positively (protein acidic rich in cysteine (SPARC)), or negatively (cystatinC and
fibulin-5), regulate the signaling.54,55
Due to the universal role of TGF−β signaling, dysfunction of the pathway can cause
cardiovascular disease, immunity abnormality, connective tissue disease mainly from
the disorder of epithelial to mesenchymal transition (EMT), reproductive disorders,
metabolic disorders, skeleton and muscular disorders from imbalance of bone
homeostasis and muscle dystrophy, development defect due to the break down of
asymmetrical distribution of TGF−β  signaling especially during embryo
development(Table 2&3).5
In conclusion, the complexity of TGF−β superfamily signaling exerts a wide range of
influences on cellular functions and normal homeostasis in a contextual manner and on
varied levels.
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Table 2. Germ-line mutations in TGF−β superfamily members in human disease (cited from Blobe et al.,
BBA, 1782(2008)197-228)
Table 3. Alterations in TGF−β superfamily members in sporadic human disease (cited from Blobe et al.,
BBA, 1782(2008)197-228)
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2. TGF−β signaling and Hematopoiesis
2.1 Hematopoiesis
Hematopoiesis is a process to generate all the kinds of blood cells. It is a complex
interplay between the hematopoietic stem cells(HSC) and their environment, which
determine the fate of blood cells to stay quiescent, or proliferate, differentiate, self-
renew, or apoptosis. HSCs, under control of a variety of growth factors, divide into two
lineages, the lymphoid one giving rise to B,T and NK cells, the myeloid one
differentiating to red blood cells(RBC), platelets, monocytes and granulocyte. It starts in
the aorta-mesonephros-gonad region (AGM), the extra-embryonic yolk sac(YS), the
placenta, the thymus and the fetal liver(FL) of the embryo, and settle down in bone
marrow(BM) after birth. By the mutated estrogen receptor labeling system under
control of Runx-Cre, the cells can be traced to show the progress of embryonic
hematopoiesis. Together with many other observations in vitro culture and in vivo
transplantation experiments, we know that the YS is the starting site of embryonic
hematopoiesis, and mesodermal precursors produce both endothelial cells and
hematopoietic cells in the YS. Primitive erythrocytes, primitive myeloid cells and some
definitive myeloid progenitors and adult HSC were produced in this stage. The planceta
and the FL can provide an appropriate environment for HSC maturation and/or
expansion.56,57
Figure 4.
Regulatory effects of
TGF−β on the growth/
proliferation and
maturation/differentiati
on of developmentally
distinct hematopoietic
cells. (cited from
Hatzfeld et al., Blood,
2000 (96) 2022-37)
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In adult BM, HSCs remain relatively quiescent without overt injury, blood loss or
exotic stimulus like irradiation or chemotherapy. HSCs undergo asymmetric division
giving rise to a new cell for differentiation, and on keeps in the pluripotent status. How
to distinguish these two daughter cells is still under investigation. Other stem cell
studies might shed a light on that. The muscle stem cell would keep template strand
DNA in the undifferentiated daughter cell, and give the newly synthesized DNA strand
for differentiated one. The epigenetic markers on the template DNA strand might
contain it original potency characteristics.58 This process continues during the lifespan
under precise modulation and cross-talking of different signaling pathways. The
differentiated cells become more functional specific and vanish in the end with a
lifespan from days to the whole life.
Notch, Wnt, TGF−β and Sonic hedgehog (Shh) signaling pathways are involved in this
delicate and large-scale cell production. Notch signaling is active in HSCs and is down
regulated when HSCs differentiate.59 Wnt signaling regulates hematopoiesis through the
pathways of Wnt/beta-catenin, Wnt/Ca2+, the planar cell polarity(PCP) and Wnt/G
protein. Shh is involved through the its influence on Stat3 and CDK.60 These signaling
are triggered by blood cells themselves in autocrine or paracrine ways, extracelluar
matrix(ECM) components, nutrients and many other chemicals from the different
microenvironments for hematopoiesis. So the hematopoiesis is a thorough collaboration
of different types of blood cells and environment.
TGF−β signaling is deeply associated in numerous steps of the hematopoiesis. Many in
vitro studies suggest that TGF−β inhibits the cell cycling of the most primitive
hematopoietic cells. In vivo, TGF−β protects HSCs from chemotherapeutic drug, like 5-
fluorouracil(5-FU).61 Administration of TGF−β in mice modulates hematopoietic
development in a lineage-specific manner. 62 TGF−β, TBRII deficient BM can cause
significant autoimmune disease.63,64 Smad4 deficient BM had HSCs renewal defect.65
Smad1 expands the hemangioblast population between embryo day2 and day2.25.66
Overexpression of Smad7 to block the entire TGF−β signaling in murine HSCs causes
increased self-renewal in vivo.67 Disruption of Smad5 gene leads to enhanced
proliferation of high-proliferative potential precursors during embryonic hematopoiesis.
68
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TGF−β also plays a critical role in thymic T cell development and peripheral T cell
homeostasis, tolerance to self antigens, and T cell differentiation during the immune
response. TGF−β signaling promotes the CD8+ T cell differentiation in by studying
TBRII deficient Rag2-/- mice.69 TBRI deletion will delay the natural CD4+Fox3+
regulatory T(nTreg) cells differentiation. TBRII deletion can reduce the number of
natural killer T (NKT) cells. The loss of naïve T cells and hypereactivation of T cell is
observed in T cell specific TBR deletion mice. Differentiation from naïve T cells to
Th1&2 cells was inhibited by TGF−β. nTreg cells differentiation was slow down in the
same mice.70 Induced Treg(iTreg) cells differentiation are accelerated under
overexpression of TGF−β1. Th17 including regulatory (rTh17) and effector (iTh17)
cells, as an critical player in innate immunity, are positively regulated by TGF−β
signaling together with IL6 trigged signaling.71,72
Many studies reveal the defects of TGF−β signaling in hematopoietic malignancies. In
acute myeloid leukemia(AML), acute promyelocytic leukemia(APL) was from t(15;17),
forming the fusion protein PML-RARα. It binds the Smad/SARA/TBRI/TBRII
complex, thereby dampening TGF−β signaling.73 Some polymorphisms in TBRI and
frameshifts in Smad4 are found in AML patient. In chronic myeloid leukemia(CML),
Evi-1, a repressor of TGF−β signaling via binding to Smad3, is elevated.74 In childhood
T-cell acute lymphocytic leukemia (ALL), Smad3 protein is absent or significantly
decreased. Smad3 deficient mice, only when combined with the loss p27kip1, develop T-
cell leukemia.75
In myeloproliferative diseases, including polycythemia vera (PV), essential
thrombocythemia (ET), and myelofibrosis with myeloid metaplasia(MMM), an
activating JAK2 mutation play a major role in most cases.76,77 However, TGF−β
signaling still has complex role. In ET, PV and MMM patients, decreased the TBRII
has been observed, suggesting this deregulation confer TGF−β resistance in the
diseases. In TPO-induced MMM phenotype in mice, the lack of TGF−β and dominant
negative TBRII expression in bone marrow can prevent the development of MMM.78 In
Chronic lymphocytic leukemia (CLL), decrease of TBR and increase of an antagonist of
TBR, TBRIII, are detected.79
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2.2. TGF−β signaling and Iron homeostasis
Iron is a trace metal for the survival of most forms of life, from animals, plants to most
bacterial species. Iron is also essential for a immune system. But, together with oxygen,
iron can constitute free oxygen radicals with oxidative stress, result in cell and tissue
damage. Therefore, it is important to control this necessary but potentially toxic
substance at a moderate (non-toxic) level. Iron homeostasis is a complex balance
between toxicity of iron overload and iron deficiency. It involved in transport, uptake,
utilization, and storage of iron at the transcriptional and translational level via many
signaling pathways.80
Ferritin and transferrin sequester iron to keep it nonreactive. Transferrin receptor 1
(TRF1) is expressed on a wide range of rapidly dividing cells, activated lymphocytes
and erythroid precursors. The ferri-reductase STEAP3 reduced Fe3+ to Fe2+.  The
divalent metal transporter 1 (DMT1) move Fe2+ across the membrane.81 Ferroportin is a
transmembrane protein in enterocytes in the duodenum, hepatocytes, macrophages, that
release iron from the inside of the cell. Most of iron related gene mRNA has a iron
responsive elements (IREs) in the UTR region forming a stable RNA hairpins with a
characteristic secondary structure. These IREs are recognized by iron regulatory
proteins (IREBPs) to regulate the mRNA transcription or degradation. 82
Hepcidin, a 25 amino acid peptide made mainly in liver, binds to ferroportin, resulting
in tyrosine phosphorylation, internalization, and ubiquitin-mediated degradation.
Hepcidin deficient mice develop hemochromatosis, which has iron overload in many
organs, whereas overexpression of hepcidin causes anemia in human and mouse.
Hepcidin gene responds to the signaling of IL6/STAT3, or BMP/Smad4. 83 Loss of
function mutants in Smad4, hemojuvelin, HFE, or TFR2 in BMP/Smad4 will also lead
to hemochromatosis similar to hepcidin deficiency. Hepcidin production is regulated by
iron, erythropoietic activity, hypoxia and inflammation, and its levels in turn modulate
plasma iron content.84
3. TGF−β signaling and tumorigenesis
Tumorigenesis consists of several steps including cell transformation, evasion of
immune surveillance, expansion and metastasis. TGF−β signaling has a numerous
17
impact on these steps. It can impact cell cytostasis, differentiation, apoptosis,
suppression of tumorigenic inflammation and stroma-derived mitogens, induce evasion
of immune surveillance, autocrine mitogen production and motility, increase the EMT,
myofibroblast mobilization, enhance extravasation, osteoclast mobilization and
secretion of metastasis-related cytokines and proteases.
TGF−β inhibits cells through CDK inhibitor and suppression of c-Myc.85  For example,
loss of function of mutants in components of TGF−β signaling, might not directly
trigger the premalignant progression, but render cell highly sensitivity to neoplasia.
TGF−β promotes cell differentiation to prevent abnormal proliferation. It also
modulates cell senescence through the regulation of the inhibitor of
Differentiation/DNA bind protein (Id).86,87,88 Deletion of Smad4 in T cell stimulates
the occurrence of polyps in mouse intestine. Dominant negative TBRII in stromal cells
get a high level of hepatocyte growth factor (HGF) that leads to hyperplasia of the
adjacent epithelia. 89 Tumor derived TGF−β also induces hypomethylation of platelet-
derived growth factor B(PDGF-B), a common mitogen found in many cancer patients.
This autocrine TGF−β can inhibit the CD8+CTLs through the repression of production
of cytolytic factors including the pre-forming protein perforin, the caspase-activating
secreted factor granzymes A and B, and the proapoptotic cytokines Fas-ligand and IFN-
γ.90 A high level of TGF−β1 was found in many cancer metastasis.91 Active TBRI can
enhance the metastasis in mouse mammary tumors induced by ErbB2/HER2,92 while
dominant negative TBRII can prevent metastasis of human prostate cancer cells when
implanted in the mouse prostate,93 but also enhance metastasis of mouse prostate tumors
caused by SV40 large T antigen.94
This multi-step intervention is pleiotropic, coordinative and context dependent
involving in many regulation levels from epigenetics mark on DNA to complex cross-
talking with other signaling pathways.
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Results
Part I: Normal erythropoiesis but severe polyposis and bleeding
anemia in Smad4 deficient mice
A part of the results presented in this section was published in: Pan, D., Schomber, T., P. Kalberer, C.P.,
Terracciano, L.M., Hafen, K., Krenger, W., Hao-Shen, H., Deng, C., Skoda, R.C. Blood. 2007;110: 3049-
3055,
Summary
The tumor suppressor Smad4 mediates signaling by transforming growth factor-beta
(TGF−β) superfamily of ligands. Previous studies showed that several TGF−β family
members exert important functions in hematopoiesis. Here, we studied the role of
Smad4 in adult murine hematopoiesis using the inducible Mx-Cre/loxP system. Mice
with homozygous Smad4 deletion (Smad4Δ/Δ) developed severe anemia 6-8 weeks after
induction (mean hemoglobin 70g/L). The anemia was not transplantable, as wild type
mice reconstituted with Smad4Δ/Δ bone marrow cells had normal peripheral blood
counts. These mice did not develop an inflammatory disease typical for mice deficient
in TGF−β receptors I and II. The same results were obtained when Smad4 alleles were
deleted selectively in hematopoietic cells using the VavCre transgenic mice. In contrast,
lethally irradiated Smad4Δ/Δ mice transplanted with wild type bone marrow cells
developed anemia similar to non-transplanted Smad4Δ/Δ mice. Liver iron stores were
decreased and blood was present in stool, indicating that the anemia was due to blood
loss. Multiple polyps in stomach and colon represent a likely source of the bleeding. We
conclude that Smad4 is not required for adult erythropoiesis and that anemia is solely
the consequence of blood loss.
Mice with a MxCre inducible double knockout (Smad4Δ/Δ and TBRIIΔ/Δ) did not display
the TBRIIΔ/Δ -driven lethal inflammation suggesting that Smad4 signaling is required to
mediate the inflammatory phenotype. Furthermore, Smad4/TBRII was dispensable for
megakaryopoiesis and erythropoiesis.
19
Introduction
Smad4 is necessary for signaling by both the TGF−β and the BMP families of ligands.
Smad4-/- mice can be expected to show severe defects in hematopoiesis. However,
Smad4-/- mice die during embryogenesis before the onset of hematopoiesis. To directly
investigate the role of Smad4 in hematopoiesis, we crossed mice with a conditional
Smad4 knockout allele  (Smad4fl/fl), and a strain containing a Cre-recombinase gene
controlled by the interferon-inducible Mx1 promoter (Mx-Cre). The Mx-Cre inducible
mouse was widely used in studies of hematopoiesis and showed high efficiency of
recombination in bone marrow and other tissues. Upon induction of Mx-Cre expression,
the conditional Smad4 alleles (fl/fl) recombined to yield dysfunctional Smad4 alleles
(Δ/Δ) and these mice developed severe anemia by 6-8 weeks after induction. To
inactivate the Smad4 conditional allele in hematopoietic cells only, we crossed the
Smad4 mice to the VavCre strain, which expresses Cre selectively in hematopoietic
cells. We show that erythropoiesis was not directly affected by the loss of Smad4.
Rather, anemia is the consequence of blood loss from polyps that rapidly form in the
stomach and colon of these mice.
TGF−β signaling through the TBRII is mediated by Smad4, but a Smad4-independent
pathway also exists. Furthermore, Smad4 also mediates the signals from other type II
receptors.23 W e  investigated the Smad4/TBRII pathway in hematopoiesis by
transplanting Mx-Cre induced Smad4/TBRII double excised bone marrow cells into
wild type BL6 recipients. No weight loss and inflammatory symptoms were observed,
whereas lethal inflammation caused by single TBRII deletion bone marrows was
showed in other reports.63 64
To study more linage-specific impact of gene expression in hematopoiesis, a mouse
strain containing platelet factor 4 (Pf4) promoters driven Cre (Pf4-Cre) was developed
in our lab, 95 which can direct expression of Cre recombinase to megakaryocytes and
precursors. This new strain using a bacterial artificial chromosome (BAC) clone
containing the entire mouse Pf4 promoter, can avoid position effect variegation
compared to old relative short promoter transgene means. We crossed this Pf4-Cre
20
strain with TBRIIfl/fl and Smad4fl/fl to obtain the Pf4-Cre;TBRfl/fl;Smad4fl/fl strain. This
megakaryocyte-specific TBR and Smad4 double deficient strain shows normal platelets.
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Results
 Figure 1
Genomic structure of Smad4
conditional knockout allele. The
probe used for Southern blot is
indicated by a thick horizontal line.
A) The wild type allele of Smad4
with EcoRV sites located in introns 7
and 9 is shown. B) The conditional
allele (fl) with insertion of two loxP
sites (triangles) and an additional
EcoRV site. C) The deleted allele
after Cre recombination (Δ). S1-S5,
position of primers used for
genotyping. D) Southern blot of
DNA from bone marrow digested
with EcoRV is shown. Arrows
indicate the positions of the wild type
allele (wt), the floxed conditional
allele (fl), and the deleted allele after
Cre recombination (Δ).
Mice with induced deletion of Smad4 develop severe anemia
Four weeks after Mx-Cre induced excision of Smad4fl/fl, the resulting Smad4Δ/Δ mice
developed anemia and after 8 weeks the hemoglobin concentration and hematocrit were
decreased to 30% of normal values (Figure 2A). The mean corpuscular volume (MCV)
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was unchanged, but the reticulocyte count was strongly increased. The white blood
count and platelet levels remained unchanged. The Smad4Δ/Δ alleles were detectable by
PCR in 39/40 bone marrow derived colonies (not shown). The apparent half-life of
erythrocytes from Smad4Δ/Δ mice was reduced to 10-12 days, while the half-life in
Smad4fl/fl control mice was 23 days(Figure 2B). A direct antiglobulin test showed no
evidence for IgM or IgG surface antibodies on erythrocytes from Smad4Δ/Δ mice,
arguing against autoimmune-antibody-meditated hemolytic anemia (not shown). The
apparent reduction of the erythrocyte half-life in circulation can be explained by
compensatory increase in regeneration, marked by massive reticulocytosis (Figure 2)
and increased erythropoietin serum levels (>5000 pg/ml, n=5; normal range 50-200
pg/ml, n=4).
Smad4 is dispensable for adult murine erythropoiesis
To determine whether the observed anemia was cell-autonomous, bone marrow cells
from Mx-Cre;Smad4fl/fl mice and controls were transplanted into lethally irradiated
recipient mice. Eight weeks after bone marrow transplantation, the mice were sacrificed
Figure 2 Smad4Δ/Δ mice developed
anemia and shortened erythrocytes life
span after induced Smad4 deletion. A)
Hemoglobin,  hematocrit, reticulocytes,
leukocytes, mean corpuscular volume
(MCV) and platelets in Smad4Δ/Δ mice
(n=3), Smad4fl/fl (n=4) and S m a d 4Δ/+
(n=8) were plotted against weeks post
induction. The p-values were calculated
by the Student’s t-test. B) Measurement
of erythrocyte half-life by biotin
labeling.
A B
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and peripheral blood counts were performed (Figure 3). The red blood cell parameters
as well as white blood counts and platelets remained normal (Figure 3). The recipients
of Smad4Δ/Δ bone marrow cells did not show any signs of inflammatory disease typical
for knockouts of the TGF−β receptors (i.e. absence of weight loss, leukocytosis, signs
of inflammation of the eyes and upon autopsy absence of organ damage). Chimerism of
recipient mice was determined in peripheral blood by assessing the ratio of CD45.2
donor cells to CD45.1 recipient cells by flow cytometry. Both groups of mice displayed
a ratio of donor to recipient cells of greater than 100:1 (Table 2). No differences in B
cells (B220), T cells (CD3), and myeloid cells (Gr-1) were detected in bone marrow.
Deletion of the floxed Smad4 alleles was found by PCR in DNA from peripheral blood
cells of donor Smad4Δ/Δ mice (not shown). Thus, anemia was not transplantable with
Smad4-deficient bone marrow cells, indicating that Smad4 is dispensable for adult
murine erythropoiesis.
.
To confirm this observation in a system not depending on transplantation, we generated
mice with a hematopoietic specific deletion of Smad4. The VavCre strain has been
shown to excise loxP target sequences in hematopoietic cells only.96 The resulting
VavCre;Smad4fl/fl mice had normal blood counts and showed no symptoms of
inflammation (Figure 4). We also confirmed practically complete excision of Smad4 in
Figure 3 Transplantation of
Smad4Δ/Δ bone marrow cells
into wild type recipient mice
did not  lead to the
development of anemia.
Hemoglobin, hematocrit, mean
corpuscular volume (MCV),
reticulocytes, leukocytes and
platelets remained stable in
control and experimental
group. Eight recipients of
Smad4Δ/Δ bone marrow cells
and 4 recipients of Smad4fl/fl
controls were analyzed.
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peripheral blood cells of these mice by PCR (Figure 1E). These results implied that host
factors might be causing the anemia phenotype.
Table 2 Hematopoietic lineage distribution in bone marrow of wild type recipient mice
transplanted with Smad4Δ/Δ or Smad4fl/fl bone marrow
Smad4Δ/Δ Smad4fl/fl
(n=4) (n=4)
CD45.2+ 87.4 ± 3.3 91.1 ± 3.2
CD45.1+ 0.24 ± 0.1 0.50 ± 0.4
B220+ 8.4 ± 2.1 5.8 ± 0.2
CD3 2.5 ± 0.9 2.4 ± 0.6
Gr1 14.8 ± 1.2 14.4 ± 1.3
Donor cells (CD45.2+), recipient cells (CD45.1+)
Anemia of Smad4Δ Δ mice is non cell-autonomous
To determine if anemia is caused by the host environment, bone marrow from wild type
C57BL/6J mice was transplanted into lethally irradiated Mx-Cre;Smad4fl/fl and Smad4fl/fl
control mice. From week 2-4 after pIpC-induced deletion of Smad4, recipients began
developing anemia (Figure 5). Interindividual differences in the severity of anemia were
observed in Smad4Δ/Δ mice. The control Smad4fl/fl recipient mice remained healthy
Figure 4 VavCre;Smad4fl/fl mice did
not develop anemia. Peripheral
blood parameters were determined
in 10 weeks old mice.
VavCre;Smad4fl/fl (Δ/Δ),
VavCre;Smad4fl/+ (Δ/+) and
Smad4fl/fl (fl/fl). Dots represent the
values of individual mice,
horizontal lines indicate the mean.
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without any changes in blood parameters. These results demonstrate that anemia of
Smad4Δ/Δ mice is caused by alterations outside of the hematopoietic system.
Smad4Δ/Δ mice show severe iron deficiency
The presence of hypochromic erythrocytes at later stages of anemia in Smad4Δ/Δ mice
(Figure 6A) suggested that iron deficiency can be involved in the pathogenesis of
anemia. Liver iron in Smad4Δ/Δ mice 4 weeks after pIpC induction was decreased to
23% (2.6±0.3 µmol/g, n=6), as compared to liver iron of Smad4fl/fl mice (11.5±4.0
µmol/g, n=6) or wild type C57BL/6J (16.6±4.7 µmol/g, n=3). No differences in plasma
transferrin (Tf), determined by ELISA specific for mouse Tf, were found between
Smad4Δ/Δ mice (1.9 ± 0.2 µg/l, n=6) and Smad4fl/fl (1.9 ± 0.9 µg/l, n=10) or wild type
BL6 mice (1.7 ± 0.08 µg/l, n=3). We determined the expression of genes that are
involved in iron metabolism by quantitative PCR (Figure 6B and 5C). The efficiency of
Figure 5 Transplantation of wild
type bone marrow into Smad4Δ/Δ
recipients leads to anemia.
Hemoglobin, hematocrit, mean
corpuscular volume (MCV),
reticulocytes, leukocytes and
platelets are shown. Three individual
Smad4Δ/Δ recipient mice (#1, #2, and
#3 with open symbols) developed
anemia with individual differences in
severity and kinetics. Asterisks
denotes significant differences at 4
weeks (p≤ 0.03; Student’s t-test).
The values for the Smad4fl/fl control
recipient mice (filled triangles) are
shown as the mean of 6 mice with
standard deviation.
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Cre-mediated excision in the livers of Smad4Δ/Δ mice measured by Southern blot was
ranging 66-96% (not shown) and the expression of Smad4 mRNAs was severely
Table 1 Sequences of primers used for quantitative RT-PCR
Gene Forward primer Reverse primer
Smad4 GTTCAGGTAGGAGAGACGTTTAAGGT CCTTTACATTCCAACTGCACTCCT
Hepc CCTATCTCCATCAACAGATG AACAGATACCACACTGGGAA
Fpn AAGGATTGACCAGCTAACCAACA CAGCCAATGACTGGAGAACCA
Dcytb GCAGCGGGCTCGAGTTTA TTCCAGGTCCATGGCAGTCT
Dmt1 AACCAACAAGCAGGTGGTTGA CTTTGTAGATGTCCACAGCCA
Transferrin TTGTGCCATCCCATCACAAC CTAGTGTCCGATGCCTTCACC
Hephaestin TTGTCTCATGAAGAACATTACAGCAC CATATGGCAATCAAAGCAGAAGA
Hfe CTGAAAGGGTGGGACTACATGTTC GGACACCACTCCCAACTTCGT
Tfr1 CAGAAAGTTCCTCAGCTCAACCA GTTCAATTCAACGTCATGGGTAAG
Tfr2 AGCTGGGACGGAGGTGACTT TCCAGGCTCACGTACACAACA
Sft CTGTGCTCATTGAAGAGGACCTT TCTGGTTGCTTTCTCAGTCACG
reduced (Figure 6B). To assure that only the full length mRNA was measured, the
forward primer (Table 1) used for the quantification of the full length Smad4 mRNA
was placed in exon 8, which is deleted by Cre-mediated excision. We also determined
the expression of genes involved in the regulation of iron metabolism. Hepcidin (Hepc)
mRNA was severely decreased, whereas the expression of divalent metal transporter 1
(Dmt1), cytochrome b reductase 1 (Dcytb), ferroportin 1 (Fpn), and transferrin (Tf)
remained unchanged (Figure 6B). In the duodenum, the floxed Smad4 allele was
excised only by 4-8% (not shown) and Smad4 mRNA was just merely decreased, while
Dmt1 and Dcytb increased 5-50 fold, and transferrin receptor 2 (Tfr2) increased 2-20
fold (Figure 6C). Other iron related genes, such as major histocompatibility complex
class I-like protein (Hfe), transferrin receptor 1 (Tfr1), hephaestin (Heph), and
stimulator of Fe transport (Sft) showed no significant changes in expression (Figure
6C). Taken together, these changes fit well with a state of increased iron uptake and
demand.
Smad4, small mutants (C. elegans) and mothers against decapentaplegic homolog 4 (Drosophila);
Hepc, hepcidin; 1 Fpn, ferroportin; Dcytb, cytochrome b reductase 1; Dmt1, divalent metal
transporter 1; Tf, transferrin; Heph, hephaestin; Hfe, major histocompatibility complex class I-like
protein; Tfr1, transferrin receptor 1; Tfr2, transferrin receptor 2;  Sft, stimulator of Fe transport
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Polyps in stomach and colon cause blood loss in Smad4Δ/Δ mice
Histopathology of the GI tract of Smad4Δ/Δ mice revealed polyps in stomach and colon
(Figure 7), but not in the small intestine. Most of them were histologically characterized
by a branching architecture reminiscent of hyperplastic lesions, mostly with foci of low-
and/or high-grade dysplasia. Moreover, “serrated” aspects of the polyps were also
detected focally. Additionally, colon polyps frequently displayed cystic changes. None
of the gastric or colon polyps fulfilled the criteria of “juvenile polyps”, as they lacked
the typical histological features of such lesions, e.g. prominent stroma overgrowth. To
show that iron deficiency in Smad4Δ/Δ mice is due to GI bleeding, we collected stool
over several weeks and determined the presence of heme by the hemoccult assay
(Figure 8). Bleeding was detectable in all mice, but with variable onset and duration. In
some mice, bleeding started 17 days after pIpC induction of Smad4 deletion, whereas in
others the onset was delayed until 31 days. At the time of the first detectable bleeding
Figure 6 Smad4Δ/Δ mice display severe iron
deficiency anemia. A) Hypochromic
erythrocytes in Smad4Δ/Δ mice. Cell volume was
plotted against hemoglobin concentration. Left
panel, normal control. Right panel shows
hypochromic red blood cells (<220 g/L) and
volume increase (> 75 fl) due to reticulocytosis
in Smad4Δ/Δ. B) In liver, Smad4 and hepcidin
(Hepc) expression are almost abrogated, and
ferroportin 1 (Fpn) is slightly decreased.
Cytochrome b reductase 1 (Dcytb), divalent
metal transporter 1 (Dmt1) and transferrin (Tf)
were unchanged. C) In Duodenum, Smad4, Fpn,
hephaestin (Heph), major histocompatibility
complex class I-like protein (Hfe), transferrin
receptor 1 (Tfr1) and stimulator of Fe transport
(Sft) were unchanged, and Dmt1, Dcytb, and
transferrin receptor 2 (Tfr2) were dramatically
increased. Smad4fl/fl littermates were chosen as
controls. The p-values were calculated by
Student’s t-test.
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the mice did not yet display severe anemia and the severity of anemia did not correlate
with the time of onset of bleeding.
areas.
Figure 8  Fecal occult blood test in
Smad4Δ/Δ mice. A total of 13 mice were
analyzed (numbered in y-axis). Time in
weeks after first pIpC injection is shown
on the x-axis. Horizontal bars represent
the duration of the stool collection;
empty box, negative hemoccult tests;
filled boxes, positive hemoccult tests
Figure 7 Stomach and colon polyp formation
in Smad4Δ/Δ mice. Left panel shows a
Smad4fl/fl control mouse, right panel shows a
Smad4Δ/Δ mouse. Gross macroscopy of
stomach (a, b), histological hematoxylin-
eosin staining of stomach (c, d, e, f) and
colon (g, h, i, j) with magnified view of the
boxed
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Smad4 deficiency increase adult T cells proliferative capacity, but allows normal T
cell development and has no effects on B cells development
Even though no difference in T cells (CD3) was found in Smad4 deficient donor bone
marrow cells in normal recipients, in peripheral blood, higher percentage of CD3
positive cells was observed compared to the controls (45.8±5.7% vs 23.0±1.3%, p<0.05,
n=4 respectively) and B cell remain unchanged (46.9±5.8% vs 37.8±2.8%, p>0.05, n=4
respectively). Furthermore, Vav-Cre;Smad4fl/fl mice also display the similar phenotype
(Figure 9). To examine whether this T cells difference is coming from abnormal T cells
development, Vav-Cre;Smad4fl/fl mice at the age of 6 weeks were sacrificed to collect
thymus cells for flow cytometry analysis of CD25,CD44 and Lin- markers. The results
showed no difference in TN1-4 stages, four T cells development steps. This implies a
role of Smad4 in expansion of T cells instead of development.
Mice bone marrows with Mx-Cre induced Smad4/TBRII double deletion cause no
inflammatory symptom in normal BL6 recipients
To achieve double deletion of Smad4 and TBR in hematopoiesis, bone marrow cells
from pIpC-induced Mx-Cre;TBRfl/fl;Smad4fl / f l  and controls were transplanted into
lethally irradiated recipient mice. Eight weeks after bone marrow transplantation, mice
were subject to phlebotomy to perform the peripheral blood counts. Successful
transplantation was confirmed by analyzing the ratio of CD45.2 donor cells and CD45.1
recipient cells with flow cytometry, and excision of Smad4 and TBR was confirmed by
PCR from peripheral blood samples.
Figure 9. Smad4 deficiency increased T
cells in peripheral blood. B cells and T
cells lineage were performed by flow
cytomety analysis. A) Wild type BL
recipient mice reconstituted with bone
marrow cell from Smad4Δ/Δ (n=4), or with
Smad4fl/fl (n=4) background were analyzed
10 weeks after transplantation. B)
VavCre;Smad4fl/fl (Δ /Δ), VavCre;Smad4fl/+
(Δ/+) and Smad4fl/fl (fl/fl) mice in 10-week-
old. * means statistical significance. The p-
values were calculated by Student’s t-test.
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These recipient mice had no weight loss (Figure 10) and showed no symptom as
described in another report with single TBRII-deficient bone marrow cells
transplantation. The blood counts in these mice were also normal (Figure 11).
Figure 10. Transplantation of
Smad4Δ/Δ;TBRIIΔ/Δ bone marrow
cells into wild type recipient
mice did not lead to mice show
normal growth rate. The weight
of wild type BL recipient mice
reconstituted with bone marrow
cell from Smad4Δ/Δ /TBRIIΔ/Δ
(Δ/Δ , n=5), or with Smad4fl/fl/
TBRIIfl/fl (fl/fl, n=5) background
were monitored up to 10 weeks
after transplantation.
Figure 11. Transplantation of
Smad4Δ/Δ /TBRIIΔ/Δ bone marrow
cells into wild type recipient mice
did not lead to any inflammation
symptoms. Hemoglobin, hematocrit,
mean corpuscular volume (MCV),
reticulocytes, leukocytes and
platelets remained stable in control
and experimental group. Five
recipients of S m a d 4Δ/Δ /TBRIIΔ/Δ
bone marrow cells and 5 recipients
of Smad4fl/fl/ TBRIIfl/fl controls were
analyzed.
31
Double deletion of Smad4/TBRII in megakaryocytes has no effect on circulating
platelet counts
Because the above study of double deletion of Smad4 and TBR in hematopoiesis was
performed in artificial environment due to transplantation, and Mx-Cre;TBRfl/fl;Smad4fl/fl
mice developed lethal symptom in normal physiological condition after deletion
induction, we used Pf4-Cre;TBRfl/fl;Smad4fl/fl mice to study megakaryopoiesis under
natural physiological condition. The Pf4-Cre;TBRfl/fl;Smad4fl/fl mice with megakarycyte-
specific excision did not show any alterations in circulating platelet counts (Figure 12),
in agreement with the above results obtained by transplantation of  with pIpC-induced
Mx-Cre;TBRfl/fl;Smad4fl/fl double gene deletion bone marrow cells into normal
recipients.
Figure 12. Double deletion of
Smad4/TBRII in megakaryocyte has
no effect on circulating platelet
counts. Peripheral blood parameters
were determined in 6 weeks old
mice. P f 4 C r e;Smad4fl/fl/TBRIIΔ/Δ
(Δ/Δ), and Smad4fl/fl/ TBRIIfl/fl(fl/fl)
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Discussion
Our results from transplantation of Smad4Δ/Δ bone marrow into wild type recipients and
deletion of Smad4 selectively in hematopoietic cells in VavCre;Smad4fl/fl mice
demonstrate that Smad4 signaling is dispensable for adult erythropoiesis in vivo (Figure
3 and 4). The red blood cell parameters in peripheral blood were normal. Our study is
consistent with the results of an in vitro study that examined cultured human CD34+
hematopoietic stem/progenitor cells under shRNA mediated Smad4 knock-down.15 We
also found normal megakaryopoiesis in our study, arguing that the decrease in
circulating platelet counts and increase in megakaryocyte numbers in mice injected with
TGF−β protein in vivo is mediated by Smad4-independent signaling.97 The white blood
counts of neutrophil, basophil and eosinophil granulocytes as well as monocytes and
lymphocytes were normal. The severe anemia observed in Smad4Δ/Δ mice is caused by
blood loss.
TGF−β signaling plays an important role in immune surveillance. By producing the
immunosuppressive cytokine TGF−β, tumors may escape from immune surveillance via
inhibiting the expression of cytolytic genes.90 TGF−β receptor II (TBR II) dominant-
negative approaches led to autoimmune inflammatory disease and spontaneous T-cell
activation.98 Mice with TBR II deletion in bone marrow showed not only increased
CD8+ proliferation in vivo, but also developed a lethal inflammatory disease,69,99 and
the TBR II deficient cells of hematopoietic origin, most likely T cells, can induce
multifocal inflammatory disease in a dominant way. On the contrary, our Smad4Δ/Δ bone
marrow recipients and VavCre;Smad4fl/fl mice were healthy and did not show any signs
of inflammatory disease. This result implies that inflammation is not mediated through
TBRII-Smad4 pathway. It remains to be determined, whether this effect is mediated by
the traditional TGF−β pathway with an alternative downstream mediator like TIF1, or
by crosstalk with other signaling through MAPK, JNK, PI3K, or other mediators.
Furthermore, these two strains both show higher T cells number in peripheral blood, but
TN1-4 flow cytometry analysis shows normal T cells development. This observation is
consistent with a previous report showing that TBRII deficient thymocytes develop
normally but demonstrating increased CD8+ proliferation in vivo,69 which implies that
this enhanced proliferative capacity might be due to TBRII/SMAD4 signal blockage.
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An interesting finding is that double deletion of TBRII and Smad4 did not cause any
symptom of inflammation, which is in contrast to multi-focal lethal inflammation
caused by single deletion of TBRII. Due to complex cross-talking with other signaling
pathways in the TGF−β signaling network, that whether Smad4 suppressed gene is
required for TBBRII deficient-mediated inflammation symptom still remain unclear.
By using mice with megakaryocyte-specific Cre expression, we can investigate the role
of TBRII and Smad4 in magakaryopoiesis. Previous reports showed the inhibitory
effect of TGF−β1 on CFU-Megs in vitro,95 decreased platelets with TGF−β1
administration in mouse, and lower mRNA expression of TGF−β1 and its receptors in
patients with myeloproliferative disorders. Single deletion of TBRII (Tibor Schomber’s
PhD thesis, Basel University) or Smad4 has been proven to have no effect on
megakaryopoiesis. Our double deletion experiment in Pf4-Cre transgenic line is firmly
in agreement with this observation. Together with transplantation with Mx-Cre induced
double deletion bone marrows, the potential role of TBRII-Smad4 pathway in
megakaryopoiesis was excluded.
Smad4 is a tumor suppressor gene, and Smad4 mutations are frequently detected in
pancreatic cancer, colon cancer, gastric polyps and adenocarcinomas.100-104 Mice
heterozygous for the Smad4 knockout appear normal, but develop gastrointestinal
polyps after a long latency with loss of heterozygosity in the epithelial cells.105,106 Our
Smad4Δ/Δ mice, which have complete excision in bone marrow as well as partially in
stomach (10-50%), started bleeding around day 20 after pIpC induction (Figure 8), and
quickly developed a severe anemia and significant polyps in the GI tract without
formation of real tumors before they needed to be sacrificed. Ablation of TGF−β by T-
cell specific over-expression of dominant negative TBR II can accelerate azoxymethane
induced colon carcinogenesis through increased T-cell production of IL6.107 Recently, it
was reported that T cell specific deletion of Smad4 leads to spontaneous epithelial
tumors throughout the GI tract. Mice in this study displayed weight loss starting 3
month after birth and eventually developed clinical features of systemic illness. In
contrast, mice with epithelial-specific deletion of Smad4 remained free of polyps,
suggesting that polyp formation and tumorigenesis are induced by Smad4 deficient T
cells.70 Our Mx-Cre;Smad4Δ/Δ mice developed polyps with a much faster kinetics and
34
since they suffered from severe bleeding anemia, we can not examine tumor
progression. When Mx-Cre induced Smad4Δ/Δ mice were used as recipients for the
transplantation of normal bone marrow cells, we observed rapid evolution of anemia
(Figure 5), which against that the dispensable role of Smad4 in polyps onset. 70
However, we cannot exclude that some host T cells deficient for Smad4 remained
functional in these mice.
Recently, shRNA mediated knockdown of bone morphogenic protein type II receptor
(Bmpr2), another member of the TGF−β receptor family, resulted in severe mucosal
hemorrhage, gastrointestinal hyperplasia and blood loss.66 This phenotype was related
to vascular dysmorphogenesis. Other studies suggested that malformed vessels are
present in polyps of SMAD4-/- juvenile polyposis.108In contrast, no malformations of
blood vessels were observed in polyps from our Smad4Δ/Δ mice.
Our Smad4Δ/Δ mice showed an almost complete loss of hepcidin mRNA expression in
liver. This can be due to two mechanisms. One, liver-specific Smad4 deletion results in
markedly decreased hepcidin transcription,108 and second, increased erythropoiesis due
to anemia suppresses the production of hepcidin.109 In our mice, both mechanisms are
likely to be contributing to the strongly suppressed hepcidin expression.
Our results demonstrate that Smad4 is dispensable for adult erythropoiesis and suggests
that polyp formation in mice with homozygous deletion of Smad4 is not entirely T cell
dependent. Same results were recently reported by Karlsson and colleagues.65 The
Smad4Δ/Δ mice can be used to further study polyp formation and the interplay between
the inflammatory response and alterations in the epithelial cells and the stroma of the GI
tract.
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Part II: A pilot study of TGF−β signaling and iron homeostasis
(Dejing Pan and Radek Skoda, unpublished data)
Summary
Iron is a critical factor for the oxygen-transport protein hemoglobin in red blood cells
and complex of the electron transport chain in mitochondria. Hepcidin, a peptide
synthesized in liver, regulates the iron flux of cellular iron through interacting with
ferrportin. Unlike the up-regulation of hepcidin, its down-regulation was not well
studied. After phlebotomy, hepcidin expression drops rapidly.  We  examined the
change in expression of the iron metabolism related genes in the background of blocked
expression of Smad4, Smad4/TBRII, and Smad4/HDAC1, which were specifically
induced in the liver. After phlebotomy, in Smad4 deficient liver, Atoh8 and Id1 were
down-regulated, and Bmp6 and Smad7 slightly decrease. In Smad4/TBRII deficient
liver, Atoh8, Id1 and Smad7 were down-regulated, and Bmp6 does not show significant
decrease. In Smad4/HDAC1 deficient liver, the expression Atoh8, Id1, Bmp6 and Smad7
were significantly down-regulated. Tmprss6 and Hjv mRNA remain unaltered in all the
mice strains.
Introduction
Iron homeostasis consists of a complex regulatory network that regulates proteins
involved in transport, uptake, utilization, and storage of iron, at the transcriptional and
translational level via many signaling pathways. Due to toxic effects of free iron
radicals, the iron homeostasis has to be systemically controlled by stringent balance of
intestinal iron uptake, and iron efflux of macrophages and hepatocytes.
Hepcidin plays a central role in directing the use and storage of iron. It works through
binding to ferrportin, a cell surface iron exporter in enterocytes, macrophages and
hepatocytes, leading to its internalization and degradation. The circulating iron pool is
one tenth of the daily requirements, thus demanding a high turnover rate. Loss of
ferrportin from the cell surface inhibits iron release and causes failure to meet the need
of rapid iron cycling, thus resulting in iron deficiency. 110
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Hepcidin normally functions to reduce plasma iron levels and increased level of
hepcidin can cause systemic anemia.84
Hepcidin simulation has been reported in many reports. The BMP/Smad4 signaling has
been demonstrated to be an important signaling pathway for hepcidin expression and
several of its components have been associated with it. Hemojuvelin (Hjv), as a BMP
co-receptor, binds BMP receptor and helps activate hepcidin expression.83A liver-
specific deletion of Smad4 gene in mice results in decreased hepcidin expression and
causes hemochromatosis, an iron overload of organs.111
However, the pathway to down-regulate hepcidin expression was not well known.
Gene expression of Atoh8, Bmp6 , Id1, and Smad7 has been reported to positively
correlate with hepcidin level and to iron burden caused by iron-enriched diets in a long
time schedule. Tmprss6 is a trans-membrane serine protease and is a newly discovered
protein involved in the hepcidin repression. A recent report shows that HDAC
inhibition increased hepcidin expression in HCV replicating cells.115 Due to close
interaction with Smads, whether HDAC1 participates in the hepcidin expression was
investigated here.
We wanted to find out how these above-mentioned genes would react to a sharp
reduction of hepcidin, as in the case of anemia or acute bleeding, in partially defective
TGF−β signaling backgrounds. After phlebotomy, erythropoiesis was highly activated
and hepcidin expression was rapidly decreased. Using pIpC-induced Mx-Cre mice, in
which high excision of loxp target genes occurs in the liver, we were investigating the
possible effects of Smad4, Smad4/TBRII, and Smad4/HDAC1 deficiency in the situation
of decreased hepcidin level. In these different signaling backgrounds, we examined the
Atoh8, Bmp6, Id1, Smad7, Tmprss6 and Hjv expression.
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Results
After phlebotomy, all mice showed splenomagly and decreased hepcidin expression
Mice of desired genotypes were bled 300 ul/day on two consecutive days and humanely
sacrificed 30 hours after the last bleeding. All mice examined showed a spleen weight
of around  200-400 mg, higher than the normal average weight of around 100 mg. This
enlarged spleen, termed splenomagly, is a sign of increased erythropoietic activity. In
adult mice, spleen, besides the bone marrow, also functions in erythropoiesis. In human,
the equivalent organ is liver. Erythropoietic activity is a prerequisite for the down-
regulation of hepcidin in anemia status. In all the mice that underwent phlebotomy,
hepcidin was sharply down-regulated as expected (Figure 13-15).
Smad4 deficiency does not prevent the drop of Atoh8 and Id1 mRNA level, causes a
slight decrease in Bmp6, Smad7, Hjv and Tmprss6 expression after phlebotomy
Expression was determined by real-time PCR using the following primers (Table 3).
Table 3 Sequences of primers used for quantitative RT-PCR 113
Gene Forward primer Reward primer
Hepc AAGCAGGGCAGACATTGCGAT CAGGATGTGGCTCTAGGCTATGT
Hjv TCAGAGTAATGCTTGACCTC CCGGTTCTTCCCAGATGATG
Atoh8 CACCATCAGCGCAGCCTTC CCATAGGAGTAGCACGGCACC
Id1 ACCCTGAACGGCGAGATCA TCGTCGGCTGGAACACATG
Bmp6 ATGGCAGGACTGGATCATTGC CCATCACAGTAGTTGGCAGCG-
Smad7 GCAGGCTGTCCAGATGCTGT GATCCCCAGGCTCCAGAAGA
Tmprss6 CAGTGTGAACGACATAGTCG ATAGCTGTAGCGATAACAGC
The results are shown in Figure 13. Smad4 expression level was used as an indicator for
deletion showed the relative efficiency of excision in all mouse strains in this paper. As
shown on Figure 13, the efficiency of Smad4 down-regulation induced by pIpC in liver
was demonstrated by real time PCR. As expected, hepcidin gene expression was
decreased in to 1/20 of its original level after phlebotomy. Expression profiles of these 6
iron-related genes in Smad4 deficient and Smad4fl/fl mice after phlebotomy were similar,
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showing no statistical difference. Compared with mice undergoing no phlebotomy, they
all showed 3 to 5 folds decrease of Atho8 and Id1, 15% to 35% decrease of Bmp6 and
no significant change of Tmprss6 and Hjv. In Smadfl/fl mice, Smad7 expression level was
stable, whereas in Smad4 deficient mice, Smad7 expression was reduced by 40% to
50%.
Smad4/HDAC1 deficient mice have a lower Atoh8, Bmp6, Id1 and Smad7 mRNAs
level and show unchanged Hjv and Tmprss6 expressions after phlebotomy
Figure 13.  Iron-related gene
expression in Smad4Δ/Δ liver. Smad4fl/fl
and Smad4Δ/Δ mice were performed
phlebotomy. Smad4fl/fl mice without
phlebotomy were chosen as controls.
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To explore whether HDAC1 is involved with iron metabolism, we try to use this double
deletion of Smad4/HDAC1 to study its effects on these genes expression. As shown is
Figure 14, in Smad4/HDAC1 deficient mice, Atoh8, Bmp6, Smad7 and Id1 mRNAs
reduced by 70-95%. Hjv and Tmprss6 did not give a significant change as expected.
Smad4/TBRII deficient mice do not prevent the drop of  Atoh8, Id1 and Smad7
mRNAs level and show a slight decrease of Bmp6 and normal level of Hjv and
Tmprss6 expressions after phlebotomy
As shown in Figure 15, Smad4/TBRII deficient mice can not reverse the drop down of
Atoh8, Id1, Bmp6 and Smad7 when hepcidin expression level was decreased. Tmprss6
had a slightly decrease by 25% to 37%. Hjv did not give a significant decrease.
Figure 14.
Iron-related gene expression in
Smad4Δ/Δ/HDAC1Δ/Δ mice liver.
Smad4Δ/Δ/HDAC1Δ/Δ and Smad4fl/fl/HDAC1fl/fl
mice were performed phlebotomy.
Smad4fl/fl/HDAC1fl/fl mice without
phlebotomy were chosen as controls.
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Figure 15.
Iron-related gene expression in
Smad4Δ/Δ/TBRIIΔ/Δ  mice liver.
Smad4Δ/Δ/ TBRIIΔ/Δ mice were
p e r f o r m e d  p h l e b o t o m y .
Smad4fl/fl/TBRIIfl/fl  mice without
phlebotomy were chosen as
controls.
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Discussion:
Anemia, bleeding, chemotherapy, irradiation and bone marrow transplantation in
patients decrease the hepcidin expression, increasing the intestinal iron absorption, iron
release from macrophages and hepatocytes, in order to maintain sufficient iron supply
for physiological needs such as erythropoiesis. Some inflammatory responses stimulate
the hepcidin expression and lead to anemia, while blockage of hepcidin in humans
causes different types of hemochromatosis. IL6-Jak-Stats might be responsible for
enhanced expression of hepcidin during inflammation.112 BMP/Smad4 pathway is
crucial for the regulation of the basal expression of hepcidin, as showed in many
reports. The sensor pathway responsible for detecting acute iron loss in the body
remains uncertain.
BMP/Smad4 pathway is part of TGF−β signaling. To examine if other components of
the TGF−β signaling pathway could be involved in this acute iron loss situation, we
used mice carrying in the liver inducible down-regulation of genes such as Smad4,
TBRII, and HDAC1 (a nuclear Smad4 co-factor), to study the change in gene expression
of some reported potential iron-related regulators, under the condition of phlebotomy
that mimics a physiological hepcidin drop.
By studying mice undergoing phlebotomy, we noticed even hepcidin expression
decreased 10 to 20 folds, but still remained around 10 fold to Rpl 19 house keep gene, a
calibrator in real time PCR. Interestingly, Smad4 deficiency did not exacerbate this
reduction, while liver-specific Smad4 deletion using Alb-Cre strain with 90% reduction
on Smad4 with similar efficiency in our system, will cause more than 100 fold decrease
without any exotic stress. This implies that Smad4 might be important for the basal
level regulation of hepcidin, but it does not effectively impact acute down-regulation of
hepcidin. Smad4/TBRII, and Smad4/HDAC1 double deficiency were shown to exert no
effects on this regulation, either.
We examined Atoh8, Id1, Bmp6 and Smad7 based on a new report of Kautz et al, 113
which showed the long term effect of iron-burden on gene expression profiles. Atoh8
and Id1 are clearly down-regulated in all mice undergoing phlebotomy. Bmp6 and
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Smad7 did not always show the tendency of reduction, but based on the standard of this
paper on fold change >1.5 fold, our results, to some extent, are in agreement with the
report on Bmp6 and Smad7.
Tmprss6, a trans-membrane protein, has recently been identified to be a hepcidine-
suppression regulator, and it might become a promising candidate of iron sensor. 114.
Tmprss6 defect causes hepcidin to increase and over-expression of Tmprss6 suppresses
the activation of the hepcidin promoter. The Tmprss6 expression level was measured in
liver of all three strains of Smad4, Smad4/TBRII, and Smad4/HDAC1, but no expected
significant increase was observed in Tmprss6 mRNA levels.
Hemojuvelin, identified as a BMP co-factor, coordinates the BMP signaling, positively
regulating hepcidine. Unfortunately, no expected decrease in expression or any
difference was found in this experiment, either.
In these acute hepcidine down-regulation experiments, the effects of Smad4,
Smad4/TBRII and Smad4/HDAC1 related signaling pathways were not observed. It
demonstrates that Smad4 possibly acts on maintaining the basal expression level of
hepdicin instead of functioning as a real-time sensor. Changes in Atoh8, Id1 and Bmp6
expression were confirmed. Tmprss6 and Hjv expression seemed not to be regulated as
expected.
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Part III: TGF−β signaling in tumorgenesis
(Dejing Pan and Radek Skoda, unpublished data)
Summary
Smad4 is a central mediator of TGF−β signaling pathway, thus regarded as a tumor
suppressor gene to prevent tumorgenesis. Smad4 mutation was found in hereditary
juvenile polyposis, and sporadic colon and lung cancers. T cells specific Smad4 deletion
causes the spontaneous epithelial cancers throughout the gastrointestinal tract in mice,
whereas epithelial specific deletion of the Smad4 does not. We monitored the wild-type
mice reconstituted with Smad4 deletion bone marrow cells and observed a shorter life
span compared to the controls with health bone marrow cells. The similar results were
obtained when Smad4 alleles were deleted selectively in hematopoietic cells using the
VavCre transgenic mice. Furthermore, these VavCre;Smad4 mice could be rescued by
wild-type bone marrow cells reconstitution, whereas the control mice would
significantly manifest a symptom of weight loss. Pathology study of VavCre;Smad4 has
revealed the presence of  the polyps in rectum and cecum.
Introduction
Smad4 is mediating the major signals from the upstream active receptors complex in
TGF−β signaling, even though there are a lot of cross-talkings with other signaling
pathways without the involvement of Smad4. The germ-line mutations in three TGF−β
signaling components were found in juvenile Polyposis patients, with 20% containing
Smad4  mutations, 20% containing BMPR1A mutations, and a small subset of patients
containing ENG mutations. In sporadic colorectal cancers, 16-25% patients were
identified to carry a Smad4 mutation.116,117
Kim et al., demonstrate that when Smad4 was deleted in T cells using Lck-Cre or CD4-
Cre  transgenic mice, there was a significant increase in the occurrence of
gastrointestinal tumors. However, the epithelial specific deletion using MMTV-Cre or
transthyretin-Cre line, did not lead to epithelial carcinoma anywhere in the
gastrointestinal tract.70 Here we used our model to verify these observations.
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Results
Wild type recipient mice reconstituted with bone marrows containing induced
Smad4 deletion had a shorter life span
We transplanted pIpC induced Mx-Cre;Smad4fl/fl bone marrow cells, which are Smad4-
deleted, into 5 wild type BL6 mice. Around 500 days after transplantation, only one
mouse was alive, whereas 4 of the control mice, reconstituted with Smad4fl/fl bone
marrow cells containing wild-type Smad4, were alive at day 460 and 3 alive 500 days
after transplantation (Figure 16).
Mice with hematopoietic-cell- specific deletion of Smad4 also show a sharply
shortened life span
 VavCre;Smad4fl/fl mice carry deletion of Smad4 selectively in hematopoietic cells. The
mice and their littermate controls were monitored up to more than one year (Figure 17).
Only 3 VavCre;Smad4fl/fl mice were still alive out of a total of 26, whereas 33 littermate
control mice survived among a total number of 35. VavCre;Smad4fl/fl mice started to die
Figure 16. Survival curve of wild type
BL6 mice (n=5) reconstituted with
Smad4Δ/Δ  bone marrows or bone marrow
from control mice (fl/fl) transplanted
into BL6 mice (n=4).
Figure 17. Survival curve of
VavCre;Smad4fl/fl mice (Δ/Δ; n=26) and
Smad4fl/fl (fl/fl; n=35) mice that were
chosen as controls.
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at 18 weeks. Around 50% to 60% of VavCre;Smad4fl/fl mice were positive in fecal occult
blood test, and some examined mice showed splenomegaly, which may indicate internal
bleeding in gastrointestinal tracts and a demand of compensational erythropoiesis.
Furthermore, VavCre;Smad4fl/fl mice appeared smaller than their control littermates.
VavCre;Smad4fl/fl mice reconstituted with wild type BL6 bone marrow cells reverse
their growth defect
If the shortened lifespan of VavCre;Smad4fl/fl mice is caused by the Smad4-deficient
hematopoietic cells, bone marrow cells from healthy wild type mice should rescue this
phenotype. To test this hypothesis, we transplanted bone marrow cells from wild type
BL6 mice into VavCre;Smad4fl/fl mice. As a control, we transplanted VavCre;Smad4fl/fl
bone marrow cells into VavCre;Smad4fl/fl mice, and VavCre;Smad4fl/fl bone marrow cells
into Smad4fl/fl mice. The follow up is too short to determine the effects on survival.
However, we noticed that VavCre;Smad4fl/fl recipient mice transplanted with Smad4
deficient bone marrow showed weight loss (Figure 18), whereas Smad4fl/fl recipients that
received Smad4 deficient bone marrow or VavCre;Smad4fl/fl mice that received healthy
bone marrow showed normal weight gain after transplantation.
The reason for the rapid weight loss in VavCre;Smad4fl/fl  mice that received bone
marrow cells from VavCre;Smad4fl/fl mice is unclear, but could be related to the smaller
size of older VavCre;Smad4fl/fl mice. Interestingly, the presence of recipient T cells in
Smad4fl/fl recipients that received Smad4 deficient bone marrow appears to counteract
this effect.
Figure 18 VavCre;Smad4fl/fl mice
reconstituted with normal wild type BL6
bone marrow cells reversed its growth defect.
Lethally irradiated VavCre;Smad4fl/fl
recipients (Δ/Δ) reconstituted with bone
marrows from wild type BL6 (n=5) or
VavCre;Smad4fl/fl donors (n=4)  and  Smad4fl/fl
recipients (fl/fl, n=3) reconstituted with bone
marrows VavCre;Smad4fl/fl donors were
monitored on weight up to 10 weeks after
transplantation
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Polyps formed in the rectum and the cecum in VavCre;Smad4fl/fl mice
As shown in Figure 19, histopathology of the gastrointestinal tract of VavCre;Smad4fl/fl
mice revealed polyps in rectum and cecum. Most of them were histologically
characterized by a branching architecture reminiscent of hyperplastic lesions, mostly
with foci of low- and/or high-grade dysplasia. We classified these lesions as mixed
hyperplastic/adenomatous polyps. Moreover, “serrated” aspects of the polyps were also
detected focally.
To exclude the possibility that this polyposis could be resulted from Smad4 deletions in
the epithelial cells, immunohistochemical stainings through sections of rectum and
cecum using rabbit anti-Smad4 antibody convincingly demonstrated the normal
presence of Smad4 in these polyp cells. In this way, we came to the conclusion that the
polyposis phenotype was predominantly caused by Smad4-deficient hematopoietic
cells.
Figure 19. Polyps in rectum and cecum in
VavCre;Smad4fl/fl mice. A) a typical rectum
polyps in VavCre;Smad4fl/fl mice. B)
Smad4 immunohistochemical staining
showed the positive signal in polyps
tissue.C) HE staining showed the polyps
morphology in rectum and cecum.
VavCre;Smad4fl/fl mice (Δ/Δ), Smad4fl/fl
mice (fl/fl).
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Discussion
We have demonstrated that Smad4-dependent signaling in hematopoietic cells is
required for tumor suppression in the intestinal environment. In our experiments,
VavCre;Smad4fl/fl mice manifested a phenotype of shortened lifespan, potential internal
bleeding, and polyp formation in rectum and cecum. Immunohistochemical staining of
Smad4 excluded the possibility that Smad4 deletion in polyp cells themselves could
cause the polyp formation. Thus, it points to the possibility that Smad4 in hematopoietic
cells may normally act to suppress polyposis. In agreement with this hypothesis, lethally
irradiated VavCre;Smad4fl/fl mice reconstituted with normal bone marrow cells display
perfect health, whereas the same lethally irradiated mice reconstituted with bone
marrow cells taken from VavCre;Smad4fl/fl mice clearly displayed weight loss. This
weight loss is not due to the failure of reconstitution, since the lethally irradiated
Smad4fl/fl mice reconstituted with exactly the same VavCre;Smad4fl/fl bone marrow cells
showed no similar weigh losing phenotype. In general, bone marrow cells extracted
from one donor mouse are enough for transplanting 10 to 20 recipient mice.
Even with a shorter life-span compared with controls, the lethally irradiated wild type
BL6 mice reconstituted with Smad4 deficient bone marrow still show a longer lifespan
than VavCre;Smad4fl/fl mice. One possible explanation is that in lethally irradiated mice,
there could still exist some surviving irradiation-resistant functional T cells, especially
in thymus. In general, T cells have a longer lifespan than other hematopoietic cell
lineages; they can even survive through the entire lifespan of adult. These T cell
survivors might still function partially to maintain the suppression of tumorigenesis.
The observation that Smad4fl / f l  mice reconstituted with bone marrow cells from
VavCre;Smad4fl / f l  mice show normal growth progress is quite in line with this
hypothesis. On the contrary, because VavCre;Smad4fl/fl mice do not contain Smad4 in
any hematopoietic cell lineage, so there will be no functional surviving T cells or other
potential candidate cells that maintain the normal suppression of tumorigenesis.
In conclusion, we have demonstrated that Smad4-mediated TGF−β signaling in
hematopoietic cells plays an important role in the suppression of tumorigenesis in the
epithelial cells of gastrointestinal tracts.
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Perspective
In the results part I, the studying of TGF−β signaling and hematopoiesis, we noticed the
wild type mice reconstituted with Smad4/TBRII deficient bone marrow cells from pIpC-
induced Mx-Cre;Smad4fl/fl;TBRIIfl/fl mice did not show the symptom of inflammation,
which was opposite to the observation of recipient mice with TBRII deficient bone
marrow cells. Why the additional Smad4 defect could rescue the TBRII deficiency
mediated inflammation needs more stringent evidences. Several experiments could be
performed in the future:
1) The Smad4/TBRII deficient hematopoietic lineage cells, especially immune related
lineage cells, could be isolated and their RNAs can be extracted to detect the expression
profile for figuring out potential candidate genes responsible for this inhibition.
2) At protein level, the plasma could be separated to study cytokine alteration by
cytokine protein arrays, and to explore the possible soluble factors involved with the
inhibition of inflammation. Cell surface markers’ alteration needs to be studied by flow
cytometry analysis.
3) Competitive bone marrows transplantation together with TBRII deficient bone
marrows could be performed to determine if this inhibition comes from the
hematopoietic cells’ mutual interaction.
In the results part II, we studied several iron-related gene alteration responding to the
acute bleeding with Smad4, Smad4/TBRII and Smad4/HDAC1 deficiency in liver.
We noticed all of these deficiencies are not responsible for the iron-related gene
alteration, or only in the baseline regulation. The examined iron-related genes would
respond to acute bleeding as they did in the chronic alteration of iron-burden situation.
However, all of these experiments are performed in the mRNA level, thus, in the future,
their corresponding protein products and related cell surface markers need to be
analyzed responding to this acute environmental stress.
In the last results part, we demonstrate the suppression of tumorigenesis in
gastrointestinal tracts required the Smad4-dependent signaling pathway. The clear
mechanism in this suppression needs to be carefully discerned.
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1) In future, the circulating soluble factors, related immune cytokine and cell surface
markers’ alteration need to be studied by proteomics methods or flow cytometry
analysis.
2) Due to this immune related phenotype, the factors of genetic background need to be
concerned carefully. We used SNP analysis to check the genetic background of Smad4
mice showing the strong mixture and S129 and BL6. To continue more stringent studies
in the immune system, purer genetic background is required. So that the backcross of
Smad4 mice with wild type BL6 mice must be performed more than 5 generations.
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Materials and Methods
Mice
All mice used in this study were kept under specific pathogen-free conditions and in
accordance to Swiss federal regulations. The Smad4fl/fl mice (Figure 1) were crossed
with the Mx-Cre mice, which contain Cre recombinase under control of the interferon
inducible Mx1 promoter. 118,119 TBRIIfl/fl mouse was kindly provided by Dr.J.Roes from
the University of college London. Pf4-Cre mice are from our own lab.95 VavCre mice
were kindly provided by Dr. Dimitris Kioussis. 96  HDAC1fl/fl mice were kindly provided
by Prof. Patrick Matthias in Fredrich Miescher Institute in Basel. Smad4 mice were
genotyped using the primers S1:ACTTTACAGGATGATGGTTA and
S2:GGTCAAGCAGATTACAGCAA that yield a 360 bp fragment for the floxed
Smad4 allele (Smad4fl) and 310bp for the wild type Smad4 allele (Smad4+) and in
parallel also with the primers S3:GGGCAGCGTAGCATATAAGA and
S4:GACCCAAACGTCACCTTCAC that produce a 450 bp fragment for Smad4fl and
390bp for Smad4+. The alleles carrying the Cre-induced deletion of Smad4 (Smad4Δ)
were detected with primer S5:TCCCACATTCCTCTTAGTTTTGA and primer S6:
CCAGCTTCTCTGTCCAGGTAGTA yielding a 500 bp fragment for Smad4Δ. The
efficiency of the Cre-mediated excision was assessed by Southern blot using a probe
genera ted  by  the  pr imers  CTCGAGTAGGTTAACAAGG and
CTTTATATACGCGCTTGGG located in intron 8 and exon 9 of the floxed Smad4
allele (Figure 1). Genotyping of Mx-Cre mice was performed with the primers
AGGTGTAGAGAAGGCACTTAGC and CTAATCGCCATCTTCCAGCAGG that
amplify a 300 bp fragment. Mx-Cre expression was induced by the intraperitoneal
injection of 300µg polyinosine-polycytosine (pIpC) 3 times every 2 days. Genotyping
of VavCre mice was performed with the primers CTCTGACAGATGCCAGGACA and
TGATTTCAGGGATGGACACA that give 500 bp fragment. The primers for
genotyping of T B R I Ifl/fl was TGTAATCGTTGCACTCTTCCATGT and
A G A T A A A C G A A G C C G G T G C A ,  a n d  f o r  P f 4  m i c e  i s
CCCATACAGCACACCTTTTG and TGCACAGTCAGCAGGTT
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Blood analysis
Blood was collected from the tail vein or by cardiac puncture and blood counts were
determined by the Advia 120 Hematology Analyzer using the “Multispecies Software”
(Bayer, Leverkusen, Germany). The concentration of transferrin in mouse blood plasma
was determined by Mouse Serum Transferrin ELISA Kit (ADI alpha diagnostic, TX,
USA). Direct antiglobulin test (DAT) was used for detecting IgG/IgM autoantibodies on
the membrane of erythrocytes. Phycoerythrin (PE) or fluorescein isothiocyanate (FITC)
labeled goat anti-mouse IgG/IgM was from Pharmingen BD, Belgium. Blood from New
Zealand Black (NZB) mice served as positive controls and Smad4fl/fl as negative controls
for DAT. Serum erythropoietin levels were measured with the Quantikine Mouse/Rat
Epo Immunoassay kit (R&D Systems, Abingdon, UK).
Red blood cell half-life measurement
Mouse blood cells were labeled by intravenous injection of 3mg NHS-X-Biotin (Sigma,
Germany). For analysis, capillary blood obtained by tail puncture was diluted in 3.8%
sodium citrate, spun down by 180 g, resuspended in 500ul PBS-FACS buffer
(0.5%BSA, 0.02%NaN3) and incubated 30 min at 4°C with PE-conjugated streptavidin
(Becton Dickinson, Germany).  The cells were centrifuged and the pellet was
resuspended in 1ml PBS-FACS buffer for flow cytometric analysis on a FACSCalibur
(Becton Dickinson, Germany) to determine the fraction of labeled RBCs remaining.
Quantitative RT-PCR
Total RNA was isolated from tissue using Trizol (Peqlab, Erlangen, Germany) and
reverse transcribed after random hexamer priming using the Omniscript RT kit
(Qiagen, Germany). Quantitative measurement of gene expression was carried out with
SYBR Green PCR master mix on an ABI Prism 7000 (Applied Biosystems, Foster City,
CA). The mouse R P L 1 9  mRNA assessed with the primers
ATCCGCAAGCCTGTGACTGT and TCGGGCCAGGGTGTTTTT was used for
normalization.120 Relative expression values were calculated by the ΔΔCT method using
one bone marrow sample as a calibrator that was set to the value of 1.121,122 The primer
pairs used for quantification of specific mRNAs are listed in Table 1 and were in part
described previously.123-125
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Liver iron analysis
Total iron in the liver tissues was determined by flame atomic absorption spectroscopy
under alkaline conditions on a Varian SpectrAA220 spectrometer (Varian, Switzerland)
following solubilization by tetramethylammonium hydroxide.126
Feces analysis
The feces of mice were collected over several weeks with sampling intervals of 3.5
days. The presence of blood in feces was detected by Hemoccult-R (Beckman Coulter,
Germany).
Flow cytometry
FITC- and PE-conjugated monoclonal antibodies against TER119, B220, Mac-1, GR-1,
CD45.1, CD45.2, CD25, CD4, CD11b, CD11c, Mc1.1, TCRb, TCRg-epsilon, CD19
and mouse IgG&M (Pharmingen, BD, San Diego, CA) were diluted in PBS/1% calf
serum and used for staining of single cell suspensions derived from bone marrow and
spleen. In order to get single cell suspensions, organs were grinded and cells were
filtered through a 40µm nylon mesh.
Bone marrow transplantation
Bone marrow cells from femurs and tibiae were filtered through a 40µm mesh and 3
x106 cells in 200µl HBSS (1X Hank's Balanced Salt solution with 20 mM Hepes buffer)
were injected into the tail vein of lethally irradiated (1100 cGy in two doses, separated
by 3 hours) 7-10 week old recipient mice. Mx-Cre;Smad4fl/fl  and control mice received
pIpC 10 days before being used as bone marrow donors. C57BL/6SJL-
PtprcaPep3b/BoyJ (B6.CD45.1) mice were used as the recipients. In the converse
experiment, B6.CD45.1 wild type donor bone marrow cells were transplanted into
irradiated Mx-Cre;Smad4fl/fl ,MxCreTBRfl/fl;Smad4fl/fl, or control mice. The recipient
mice received pIpC 5 weeks after transplantation. Chimerism of transplanted mice was
analyzed by flow cytometric analysis of CD45.1 and CD45.2 positive cells.
Histology
Stomach, small intestine and colon were isolated, fixed in 4% formalin and paraffin
embedded and 4µm-sections were stained with Hematoxylin and Eosin (H&E).
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The tumor suppressor Smad4 mediates
signaling by the transforming growth fac-
tor beta (TGF-) superfamily of ligands.
Previous studies showed that several
TGF- family members exert important
functions in hematopoiesis. Here, we
studied the role of Smad4 in adult murine
hematopoiesis using the inducible Mx-
Cre/loxP system. Mice with homozygous
Smad4 deletion (Smad4/) developed se-
vere anemia 6 to 8 weeks after induction
(mean hemoglobin level 70 g/L). The ane-
mia was not transplantable, as wild-type
mice reconstituted with Smad4/ bone
marrow cells had normal peripheral blood
counts. These mice did not develop an
inflammatory disease typical for mice de-
ficient in TGF- receptors I and II, suggest-
ing that the suppression of inflammation
by TGF- is Smad4 independent. The
same results were obtained when Smad4
alleles were deleted selectively in hemato-
poietic cells using the VavCre transgenic
mice. In contrast, lethally irradiated
Smad4/ mice that received wild-type
bone marrow cells developed anemia
similar to Smad4/ mice that did not
receive a transplant. Liver iron stores
were decreased and blood was present in
stool, indicating that the anemia was due
to blood loss. Multiple polyps in stomach
and colon represent a likely source of the
bleeding. We conclude that Smad4 is not
required for adult erythropoiesis and that
anemia is solely the consequence of blood
loss. (Blood. 2007;110:3049-3055)
© 2007 by The American Society of Hematology
Introduction
The members of the transforming growth factor beta (TGF-)
superfamily of ligands modulate cell proliferation, differentiation,
apoptosis, adhesion, and cell migration.1 These ligands, including
TGF-, activins, and bone morphogenetic proteins (BMPs), bind
cell-surface receptors, classified as type I and II receptors, that
contain an intracellular serine/threonine protein kinase domain.
Upon ligand activation, the type II and type I receptors form an
active ligand-receptor complex that phosphorylates members of the
Small mutants (Caenorhabditis elegans) and mothers against the
decapentaplegic homolog (Smad) family of proteins. The Smad
family members that directly interact with the receptors are called
receptor Smads (R-Smad). The type I receptors for TGF-, activin,
nodal, and myostatin phosphorylate R-Smad2 and 3, whereas the
BMPs phosphorylate R-Smad1, 5, and 8. The R-Smads associate
with Smad4, also called common partner Smad (co-Smad), and as a
complex enter the nucleus to regulate transcription. Smad6 and
Smad7 TGF- inhibit signaling through multiple mechanisms and
are called inhibitory Smads (I-Smad).2
Hematopoiesis is a tightly balanced process consisting of cell
self-renewal, differentiation, and apoptosis of hematopoietic cells.
The effects of TGF- signaling on hematopoiesis are cell and
context specific. TGF-1 has an inhibitory function in early
expansion of committed hematopoietic precursors,3 and BMP4 is
implicated in mesoderm induction and hematopoietic commitment
during embryogenesis.4 Mice deficient for TGF-1 die 3 to 4 weeks
after birth due to an inflammatory syndrome,5,6 whereas the
knockouts of the TGF- receptors I and II are embryonically lethal
during midgestation.7,8 Cells taken from embryos deficient for
TGF- receptors I and II display an increase in erythroid colony-
forming cells, consistent with an inhibitory effect of TGF- in early
expansion of committed hematopoietic precursors.8 Smad1/ and
Smad5/ mice showed defects of hematopoietic and vascular
development.9,10 Smad1 expression is sufficient to expand the
number of cells that commit to the hemangioblast fate.11 Smad5 is
dispensable for hematopoiesis in the adult mouse.12 Overexpres-
sion of Smad7 promotes self-renewal capacity of hematopoietic
stem cells (HSCs) in vivo.13
Since Smad4 is necessary for signaling by both the TGF- and
the BMP families of ligands, Smad4/ mice could be expected to
show severe defects in hematopoiesis. However, Smad4/ mice
die during embryogenesis before the onset of hematopoiesis.14,15 To
directly investigate the role of Smad4 in hematopoiesis, we crossed
mice with a conditional Smad4 knockout allele (Smad4fl/fl)16 and a
strain containing a Cre-recombinase gene controlled by the inter-
feron-inducible Mx1 promoter (Mx-Cre).17 The Mx-Cre–inducible
mouse was widely used in studies of hematopoiesis and showed
high efficiency of recombination in bone marrow.17,18 Upon
induction of Mx-Cre expression, the conditional Smad4fl/fl alleles
(fl/fl) recombined to yield dysfunctional Smad4 alleles (/) and
these mice developed severe anemia by 6 to 8 weeks after
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induction. To inactivate the Smad4fl/fl conditional allele in hemato-
poietic cells only, we crossed the Smad4 mice to the VavCre strain,
which expresses Cre selectively in hematopoietic cells under the
control of the Vav promoter.19 We show that erythropoiesis was not
directly affected by the loss of Smad4. Rather, anemia is the
consequence of blood loss from polyps that rapidly form in the
stomach and colon of these mice.
Materials and methods
Mice
All mice used in this study were kept under specific pathogen-free
conditions and in accordance with Swiss federal regulations. The Smad4fl/fl
mice (Figure S1, available on the Blood website; see the Supplemental
Materials link at the top of the online article) were crossed with the Mx-Cre
mice, which contain Cre recombinase under control of the interferon-
inducible Mx1 promoter.16,17 Smad4 mice were genotyped using the primers
S1 (ACTTTACAGGATGATGGTTA) and S2 (GGTCAAGCAGATTACAG-
CAA), which yield a 360-bp fragment for the floxed Smad4 allele (Smad4fl)
and 310-bp fragment for the wild-type Smad4 allele (Smad4), and also in
parallel with the primers S3 (GGGCAGCGTAGCATATAAGA) and S4
(GACCCAAACGTCACCTTCAC), which produce a 450-bp fragment for
Smad4fl and a 390-bp fragment for Smad4. The alleles carrying the
Cre-induced deletion of Smad4 (Smad4) were detected with primer S5
(TCCCACATTCCTCTTAGTTTTGA) and primer S6 (CCAGCTTCTCT-
GTCCAGGTAGTA), yielding a 500-bp fragment for Smad4. The effi-
ciency of the Cre-mediated excision was assessed by Southern blot using a
probe generated by the primers CTCGAGTAGGTTAACAAGG and CTT-
TATATACGCGCTTGGG located in intron 8 and exon 9 of the floxed
Smad4 allele (Figure S1). Genotyping of Mx-Cre mice was performed with
the primers AGGTGTAGAGAAGGCACTTAGC and CTAATCGCCATCT-
TCCAGCAGG, which amplify a 300-bp fragment. Mx-Cre expression was
induced by the intraperitoneal injection of 300 g polyinosine-polycytosine
(pIpC) 3 times every 2 days. VavCre mice were kindly provided by Dr
Dimitris Kioussis.19 These mice were crossed to obtain VavCre;Smad4fl/fl
mice. Genotyping of VavCre mice was performed with the primers
CTCTGACAGATGCCAGGACA and TGATTTCAGGGATGGACACA,
yielding a 500-bp fragment.
Blood analysis
Blood was collected from the tail vein or by cardiac puncture and blood
counts were determined by the Advia 120 Hematology Analyzer using
the Multispecies Software, version 2.3.01-MS (Bayer, Leverkusen, Ger-
many). The concentration of transferrin in mouse blood plasma was
determined by a mouse serum transferrin enzyme-linked immunosorbent
assay (ELISA) kit (ADI Alpha Diagnostic, San Antonio, TX). Direct
antiglobulin test (DAT) was used for detecting IgG/IgM autoantibodies on
the membrane of erythrocytes. Phycoerythrin (PE)– or fluorescein isothio-
cyanate (FITC)–labeled goat anti–mouse IgG/IgM was from Pharmingen
BD (Erembodegen, Belgium). Blood from New Zealand Black (NZB) mice
served as positive controls and Smad4fl/fl as negative controls for DAT.
Serum erythropoietin levels were measured with the Quantikine Mouse/Rat
Epo Immunoassay kit (R&D Systems, Abingdon, United Kingdom).
Red blood cell half-life measurement
Mouse blood cells were labeled by intravenous injection of 3 mg
NHS-X-Biotin (Sigma, Deisenhofen, Germany). For analysis, capillary
blood obtained by tail puncture was diluted in 3.8% sodium citrate, spun
down by 180g, resuspended in 500 L PBS-FACS buffer (0.5% BSA,
0.02% NaN3), and incubated 30 minutes at 4°C with PE-conjugated
streptavidin (Becton Dickinson, Heidelberg, Germany). The cells were
centrifuged and the pellet was resuspended in 1 mL PBS-FACS buffer for
flow-cytometric analysis on a FACSCalibur (Becton Dickinson) to deter-
mine the fraction of labeled red blood cells (RBCs) remaining.
Quantitative reverse transcriptase–polymerase chain
reaction (RT-PCR)
Total RNA was isolated from tissue using Trizol (Peqlab, Erlangen,
Germany) and reverse transcribed after random hexamer priming using the
Omniscript RT kit (Qiagen, Hilden, Germany). Quantitative measurement
of gene expression was carried out with SYBR Green PCR master mix on
an ABI Prism 7000 (Applied Biosystems, Foster City, CA). The mouse
RPL19 mRNA assessed with the primers ATCCGCAAGCCTGTGACTGT
and TCGGGCCAGGGTGTTTTT was used for normalization.20 Relative
expression values were calculated by the delta-delta cycle threshold
(CT) method using 1 bone marrow sample as a calibrator that was set to
the value of 1.21,22 The primer pairs used for quantification of specific
mRNAs are listed in Table 1 and were in part described previously.23-25
Liver iron analysis
Total iron in the liver tissues was determined by flame atomic absorption
spectroscopy under alkaline conditions on a Varian SpectrAA220 spectrom-
eter (Varian, Zug, Switzerland) following solubilization by tetramethylam-
monium hydroxide.26
Feces analysis
The feces of mice were collected over several weeks with sampling
intervals of 3.5 days. The presence of blood in feces was detected by
Hemoccult-R (Beckman Coulter, Krefeld, Germany).
Flow cytometry
FITC- and PE-conjugated monoclonal antibodies against TER119, B220,
Mac-1, GR-1, CD45.1, CD45.2, and mouse IgG and IgM (Pharmingen, BD,
San Diego, CA) were diluted in PBS/1% calf serum and used for staining of
single-cell suspensions derived from bone marrow and spleen. In order to
get single-cell suspensions, organs were grinded and cells were filtered
through 70-m nylon mesh.
Bone marrow transplantation
Bone marrow cells from femora and tibiae were filtered through 40-m
mesh, and 3  106 cells in 200 L HBSS (1 Hanks balanced salt solution
with 20 mM Hepes buffer) were injected into the tail vein of lethally
irradiated (1100 cGy in 2 doses, separated by 3 hours) 7- to 10-week-old
recipient mice. Mx-Cre;Smad4fl/fl and control mice received pIpC 10 days
before being used as bone marrow donors. C57BL/6SJL-PtprcaPep3b/BoyJ
(B6.CD45.1) mice were used as the recipients. In the converse experiment,
B6.CD45.1 wild-type donor bone marrow cells were transplanted into
irradiated Mx-Cre;Smad4fl/fl or control mice. The recipient mice received
Table 1. Sequences of primers used for quantitative RT-PCR
Gene Forward primer Reverse primer
Smad4 GTTCAGGTAGGAGAGACGTTTAAGGT CCTTTACATTCCAACTGCACTCCT
Hepc CCTATCTCCATCAACAGATG AACAGATACCACACTGGGAA
Fpn AAGGATTGACCAGCTAACCAACA CAGCCAATGACTGGAGAACCA
Dcytb GCAGCGGGCTCGAGTTTA TTCCAGGTCCATGGCAGTCT
Dmt1 AACCAACAAGCAGGTGGTTGA CTTTGTAGATGTCCACAGCCA
Tf TTGTGCCATCCCATCACAAC CTAGTGTCCGATGCCTTCACC
Heph TTGTCTCATGAAGAACATTACAGCAC CATATGGCAATCAAAGCAGAAGA
Hfe CTGAAAGGGTGGGACTACATGTTC GGACACCACTCCCAACTTCGT
Tfr1 CAGAAAGTTCCTCAGCTCAACCA GTTCAATTCAACGTCATGGGTAAG
Tfr2 AGCTGGGACGGAGGTGACTT TCCAGGCTCACGTACACAACA
Sft CTGTGCTCATTGAAGAGGACCTT TCTGGTTGCTTTCTCAGTCACG
Smad4 indicates small mutants (C elegans) and mothers against decapentaple-
gic homolog 4 (Drosophila); Hepc, hepcidin; Fpn, ferroportin; Dcytb, cytochrome b
reductase 1; Dmt1, divalent metal transporter 1; Tf, transferrin; Heph, hephaestin;
Hfe, major histocompatibility complex class I–like protein; Tfr1, transferrin receptor 1;
Tfr2, transferrin receptor 2; and Sft, stimulator of Fe transport.
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pIpC 5 weeks after transplantation. Chimerism of recipient mice was
analyzed by flow-cytometric analysis of CD45.1 and CD45.2 cells.
Histology
Stomach, small intestine, and colon were isolated, fixed in 4% formalin, and
paraffin embedded, and 4-m sections were stained with hematoxylin and
eosin (H&E). The images were viewed and captured with a Leica DMZ75
microscope (Leica, Wetzlar, Germany) and Leica DFC480 R2 camera with
1.0 plan objective, and Zeiss AX10 microscope (Carl Zeiss, Oberkochen,
Germany) and Axio CamHR camera objective Plan-Neofluar 2.5/0.075,
Plan-Apochromat 5/0.16, and Plan-Apochromat 1.0/0.45. Images were
acquired using Leica FireCam software version 1.5 and Axio CamHR
version 4.6. Brightness/contrast and color balance were adjusted using
Adobe Photoshop Elements 2.0 (Adobe Systems, San Jose, CA).
Results
Mice with induced deletion of Smad4 develop severe anemia
Four weeks after Mx-Cre–induced excision of Smad4fl/fl, the
resulting Smad4/ mice developed anemia and after 8 weeks the
hemoglobin concentration and hematocrit were decreased to 30%
of normal values (Figure 1). The mean corpuscular volume (MCV)
was unchanged, but the reticulocyte count was strongly increased.
The white blood count and platelet levels remained unchanged. The
Smad4/ alleles were detectable by PCR in 39 of 40 bone
marrow–derived colonies (not shown). The apparent half-life of
erythrocytes from Smad4/ mice was reduced to 10 to 12 days,
whereas the half-life in Smad4fl/fl control mice was 23 days (data
not shown). A direct antiglobulin test showed no evidence for IgM
or IgG surface antibodies on erythrocytes from Smad4/ mice,
arguing against autoimmune antibody–meditated hemolytic ane-
mia (not shown). The apparent reduction of the erythrocyte
half-life in circulation can be explained by compensatory increase
in regeneration, marked by massive reticulocytosis (Figure 1) and
increased erythropoietin serum levels ( 5000 pg/mL, n 5;
normal range 50-200 pg/mL, n 4).
Smad4 is dispensable for adult murine erythropoiesis
To determine whether the observed anemia was cell autonomous,
bone marrow cells from pIpC-induced Mx-Cre;Smad4fl/fl mice and
controls were transplanted into lethally irradiated recipient mice.
Eight weeks after bone marrow transplantation, the mice were
killed and peripheral blood counts were performed (Figure 2). The
red blood cell parameters as well as white blood cell counts and
platelet levels remained normal (Figure 2). The recipients of
Smad4/ bone marrow cells did not show any signs of inflamma-
tory disease typical for knockouts of the TGF- receptors (ie,
absence of weight loss, leukocytosis, signs of inflammation of the
eyes, and upon autopsy absence of organ damage). Chimerism of
recipient mice was determined in peripheral blood by assessing the
ratio of CD45.2 donor cells to CD45.1 recipient cells by flow
cytometry. Both groups of mice displayed a ratio of donor to
recipient cells of greater than 100:1 (Table 2). No differences in
B cells (B220), T cells (CD3), or myeloid cells (Gr-1) were
detected in bone marrow. Deletion of the floxed Smad4 alleles was
found by PCR in DNA from peripheral blood cells of the recipient
mice (not shown). Thus, anemia was not transplantable with
Smad4-deficient bone marrow cells, indicating that Smad4 is
dispensable for adult murine erythropoiesis.
To confirm this observation in a system not depending on
transplantation, we generated mice with a hematopoietic-specific
deletion of Smad4. The VavCre strain has been shown to excise
loxP target sequences in hematopoietic cells only.19 The resulting
VavCre;Smad4fl/fl mice had normal blood counts and showed no
symptoms of inflammation (Figure 3). We also confirmed complete
excision of Smad4 in peripheral blood cells of these mice by PCR
(Figure S1E). These results implied that host factors might be
causing the anemia phenotype.
Anemia of Smad4/ mice is non–cell-autonomous
To determine if anemia is caused by the host environment, bone
marrow from wild-type C57BL/6J mice was transplanted into
lethally irradiated Mx-Cre;Smad4fl/fl and Smad4fl/fl control mice.
From weeks 2 to 4 after pIpC-induced deletion of Smad4,
recipients began developing anemia (Figure 4). Interindividual
differences in the severity of anemia were observed in Smad4/
mice. The control Smad4fl/fl recipient mice remained healthy
without any changes in blood parameters. These results demon-
strate that anemia of Smad4/ mice is caused by alterations outside
of the hematopoietic system.
Smad4/ mice show severe iron deficiency
The presence of hypochromic erythrocytes at later stages of anemia
in Smad4/ mice (Figure 5A) suggested that iron deficiency could
be involved in the pathogenesis of anemia. Liver iron in Smad4/
mice 4 weeks after pIpC induction was decreased to 23% (2.6	
0.3 mol/g, n 6) compared with liver iron of Smad4fl/fl mice
Figure 1. Smad4/ mice developed anemia after induced Smad4 deletion.
Hemoglobin level, hematocrit, reticulocyte count, leukocyte count, mean corpuscular
volume (MCV), and platelet count in Smad4/ (n  3), Smad4fl/fl (n  4), and
Smad4/ (n  8) mice were plotted against weeks after induction. The P values
were calculated by Student t test. The error bars indicate standard deviation.
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(11.5 	 4.0 mol/g, n 6) or wild-type C57BL/6J mice (16.6	
4.7 mol/g, n  3). No differences in plasma transferrin (Tf),
determined by ELISA specific for mouse Tf, were found between
Smad4/ mice (1.9	 0.2 g/L, n 6) and Smad4fl/fl (1.9	
0.9 g/L, n  10) or wild-type BL6 mice (1.7	 0.08 g/L,
n  3). We determined the expression of genes that are involved in
iron metabolism by quantitative PCR (Figure 5B-C). The efficiency
of Cre-mediated excision in the livers of Smad4/ mice measured
by Southern blot was ranging from 66% to 96% (not shown) and
the expression of Smad4 mRNA was severely reduced (Figure 5B).
To assure that only the full-length mRNA was measured, the
forward primer (Table 1) used for the quantification of the
full-length Smad4 mRNA was placed in exon 8, which is deleted by
Cre-mediated excision. We also determined the expression of genes
involved in the regulation of iron metabolism. Hepcidin (Hepc)
mRNA was severely decreased, whereas the expression of divalent
metal transporter 1 (Dmt1), cytochrome b reductase 1 (Dcytb),
ferroportin 1 (Fpn), and transferrin (Tf) remained unchanged
(Figure 5B). In the duodenum, the floxed Smad4 allele was excised
by only 4% to 8% (not shown) and Smad4 mRNA was just merely
decreased, whereas Dmt1 and Dcytb increased 5- to 50-fold and
transferrin receptor 2 (Tfr2) increased 2- to 20-fold (Figure 5C).
Other iron-related genes, such as major histocompatibility complex
class I–like protein (Hfe), transferrin receptor 1 (Tfr1), hephaestin
(Heph), and stimulator of Fe transport (Sft) showed no significant
changes in expression (Figure 5C). Taken together, these changes
fit well with a state of increased iron uptake and demand.
Polyps in stomach and colon cause blood loss in
Smad4/ mice
Histopathology of the gastrointestinal (GI) tract of Smad4/ mice
revealed polyps in stomach and colon (Figure 6) but less frequently
in the small intestine. Most of them were histologically character-
ized by a branching architecture reminiscent of hyperplastic
lesions, mostly with foci of low- and/or high-grade dysplasia. We
classified these lesions as mixed hyperplastic/adenomatous polyps.
Moreover, “serrated” aspects of the polyps were also detected
focally. Additionally, colon polyps frequently displayed cystic
changes. None of the gastric or colon polyps fulfilled the criteria of
“juvenile polyps,” as they lacked the typical histologic features of
such lesions (eg, prominent stroma overgrowth).
To show that iron deficiency in Smad4/ mice is due to GI
bleeding, we collected stool over several weeks and determined the
presence of heme by the hemoccult assay (Figure 7). Bleeding was
detectable in all mice but with variable onset and duration. In some
mice, bleeding started 17 days after pIpC induction of Smad4
deletion, whereas in others the onset was delayed until 31 days. At
the time of the first detectable bleeding, the mice did not yet display
severe anemia and the severity of anemia did not correlate with the
time of onset of bleeding.
Figure 2. Transplantation of Smad4/ bone marrow cells into wild-type
recipient mice did not lead to the development of anemia. Hemoglobin level,
hematocrit, MCV, reticulocyte count, leukocyte count, and platelet count remained
stable in the control and experimental groups. Eight recipients of Smad4/ bone
marrow cells and 4 recipients of Smad4fl/fl controls were analyzed 8 weeks after
transplantation. Dots represent the values of individual mice; horizontal lines indicate
the mean.
Figure 3. Absence of anemia in VavCre;Smad4fl/fl mice. Peripheral blood parameters
were determined in 10-week-old mice. VavCre;Smad4fl/fl (/), VavCre;Smad4fl/
(/), and Smad4fl/fl (fl/fl). Dots represent the values of individual mice; horizontal
lines indicate the mean.
Table 2. Hematopoietic lineage distribution in bone marrow of
wild-type recipient mice that received Smad4/ or Smad4fl/fl
bone marrow
Smad4/ Smad4fl/fl
n 4 4
CD45.2 87.4 	 3.3 91.1 	 3.2
CD45.1 0.24 	 0.1 0.50 	 0.4
B220 8.4 	 2.1 5.8 	 0.2
CD3 2.5 	 0.9 2.4 	 0.6
Gr1 14.8 	 1.2 14.4 	 1.3
Donor cells (CD45.2), recipient cells (CD45.1).
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Discussion
Our results from transplantation of Smad4/ bone marrow into
wild-type recipients and deletion of Smad4 selectively in hemato-
poietic cells in VavCre;Smad4fl/fl mice demonstrate that Smad4
signaling is dispensable for adult erythropoiesis in vivo (Figures
2,3). The red blood cell parameters in peripheral blood were
normal. Our study is consistent with the results of an in vitro study
that examined cultured human CD34 hematopoietic stem/
progenitor cells under shRNA-mediated Smad4 knock-down.27 We
also found normal megakaryopoiesis in our study, arguing that the
decrease in circulating platelet counts and increase in megakaryo-
cyte numbers in mice injected with TGF- protein in vivo are
mediated by Smad4-independent signaling.28 The white blood cell
counts of neutrophil, basophil, and eosinophil granulocytes as well
as monocytes and lymphocytes were normal. The severe anemia
observed in Smad4/ mice is caused by blood loss.
TGF- signaling plays an important role in immune surveil-
lance. By producing the immunosuppressive cytokine TGF-,
tumors may escape from immune surveillance via inhibiting the
expression of cytolytic genes.29 TGF- receptor II (TBRII) domi-
nant-negative approaches led to autoimmune inflammatory disease
and spontaneous T-cell activation.30 Mice with TBRII deletion in
bone marrow not only showed increased CD8 proliferation in
vivo but also developed a lethal inflammatory disease,18,31 and the
TBRII-deficient cells of hematopoietic origin, most likely T cells,
could induce multifocal inflammatory disease in a dominant way.
On the contrary, our Smad4/ bone marrow recipients and
VavCre;Smad4fl/fl mice were healthy and did not show any signs of
inflammatory disease. This result implies that T-cell–mediated
suppression of inflammation via TGF- signaling is Smad4
independent. It remains to be determined whether this effect is
mediated by the traditional TGF- pathway with an alternative
downstream mediator like TIF1 or by crosstalk with other signaling
through MAPK, JNK, PI3K, or other mediators.
Smad4 is a tumor suppressor gene, and Smad4 mutations are
frequently detected in pancreatic cancer, colon cancer, gastric
polyps, and adenocarcinomas.32-37 Mice heterozygous for the
Smad4 knockout appear normal but develop gastrointestinal
polyps after a long latency with loss of heterozygosity in the
epithelial cells.38,39 Our Smad4/ mice, which have complete
excision in bone marrow as well as partially in stomach
(10%-50%), started bleeding around day 20 after pIpC induction
(Figure 7) and quickly developed a severe anemia and signifi-
cant polyps in the GI tract without formation of real tumors
before they needed to be killed. Ablation of TGF- by T-cell–
specific overexpression of dominant-negative TBRII could
Figure 4. Transplantation of wild-type bone marrow into Smad4/ recipients
resulted in anemia. Hemoglobin level, hematocrit, MCV, reticulocyte count, leuko-
cyte count, and platelet count are shown. Three individual Smad4/ recipient mice
(#1 [E], #2 [‚], and #3 []) developed anemia with individual differences in severity
and kinetics. *Significant differences at 4 weeks (P  .03; Student t test). The values
for the Smad4fl/fl control recipient mice (Œ) are shown as the mean of 6 mice with
standard deviation. The error bars indicate standard deviation.
Figure 5. Smad4/ mice display severe iron deficiency anemia. (A) Hypochro-
mic erythrocytes in Smad4/ mice. Cell volume was plotted against hemoglobin
concentration. (Left) Normal control. (Right) Hypochromic red blood cells
(
 220 g/L) and volume increase ( 75 fl) due to reticulocytosis in Smad4/.
(B) In liver, Smad4 and hepcidin (Hepc) expression are almost abrogated, and
ferroportin 1 (Fpn) is slightly decreased. Cytochrome b reductase 1 (Dcytb),
divalent metal transporter 1 (Dmt1), and transferrin (Tf) were unchanged. (C) In
duodenum, Smad4, Fpn, hephaestin (Heph), major histocompatibility complex
class I–like protein (Hfe), transferrin receptor 1 (Tfr1), and stimulator of Fe
transport (Sft) were unchanged, and Dmt1, Dcytb, and transferrin receptor
2 (Tfr2) were dramatically increased. Smad4fl/fl littermates were chosen as
controls. The P values were calculated by Student t test.
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accelerate azoxymethane-induced colon carcinogenesis through
increased T-cell production of IL-6.40 Recently, it was reported
that T-cell specific deletion of Smad4 leads to spontaneous
epithelial tumors throughout the GI tract. Mice in this study
displayed weight loss starting 3 months after birth and eventu-
ally developed clinical features of systemic illness. In contrast,
mice with epithelial-specific deletion of Smad4 remained free of
polyps, suggesting that polyp formation and tumorigenesis are
induced by Smad4-deficient T cells.41 Our Mx-Cre;Smad4/
mice developed polyps with a much faster kinetics and since
they suffered from severe bleeding anemia, we could not
examine tumor progression. At age 10 weeks, our VavCre;
Smad4fl/fl mice did not yet show any signs of weight loss or
systemic disease. Furthermore, when Smad4/ mice were used
as recipients for the transplantation of normal bone marrow
cells, we observed rapid evolution of anemia (Figure 4).
However, we cannot exclude that some host T cells deficient for
Smad4 remained functional in these mice.
Recently, shRNA-mediated knockdown of bone morphogenic
protein type II receptor (Bmpr2), another member of the TGF-
receptor family, resulted in severe mucosal hemorrhage, gastroin-
testinal hyperplasia, and blood loss.42 This phenotype was related
to vascular dysmorphogenesis. Other studies suggested that mal-
formed vessels are present in polyps of patients with juvenile
polyposis, found exclusively in patients carrying a mutation up to
codon 415 of SMAD4.43 In contrast, no malformations of blood
vessels were observed in polyps from our Smad4/ mice.
Our Smad4/ mice showed an almost complete loss of hepcidin
mRNA expression in liver. This could be due to 2 mechanisms:
(1) liver-specific Smad4 deletion results in markedly decreased
hepcidin transcription44; and (2) increased erythropoiesis due to
anemia suppresses the production of hepcidin.45 In our mice, both
mechanisms are likely to be contributing to the strongly suppressed
hepcidin expression.
Our results demonstrate that Smad4 is dispensable for adult
erythropoiesis and suggest that polyp formation in mice with
homozygous deletion of Smad4 is not entirely T-cell dependent.
The same results were recently reported by Karlsson et al.46 The
Smad4/ mice can be used to further study polyp formation and the
interplay between the inflammatory response and alterations in the
epithelial cells and the stroma of the GI tract.
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